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ABSTRACT 
The overarching goal of the Pathway Semantics Algorithm (PSA) is to improve the in 
silico identification of clinically useful hypotheses about molecular patterns in disease 
progression. By framing biomedical questions within a variety of matrix representations, 
PSA has the flexibility to analyze combined quantitative and qualitative data over a wide 
range of stratifications. The resulting hypothetical answers can then move to in vitro and 
in vivo verification, research assay optimization, clinical validation, and 
commercialization. Herein PSA is shown to generate novel hypotheses about the 
significant biological pathways in two disease domains: shock / trauma and hemophilia 
A, and validated experimentally in the latter. The PSA matrix algebra approach identified 
differential molecular patterns in biological networks over time and outcome that would 
not be easily found through direct assays, literature or database searches.  
In this dissertation, Chapter 1 provides a broad overview of the background and 
motivation for the study, followed by Chapter 2 with a literature review of relevant 
viii 
computational methods. Chapters 3 and 4 describe PSA for node and edge analysis 
respectively, and apply the method to disease progression in shock / trauma. Chapter 5 
demonstrates the application of PSA to hemophilia A and the validation with 
experimental results. The work is summarized in Chapter 6, followed by extensive 
references and an Appendix with additional material. 
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Chapter 1 Introduction 
Background and Motivation 
Clinical diagnosis, prognosis, and therapies for disease progression utilize 
established phenotypes and syndrome characterizations identified by the clinician based 
on patient data such as demographics, physiological observations over time, lab, 
radiology and microscopy reports, and transfusion and drug orders. Recent advances in 
the collection and assessment of molecular data offer the opportunity to use this data to 
increase understanding of disease progression, and, in the near future, to add this 
information to assist clinicians in patient care.  
There are two major approaches to molecular pattern discovery. Quantitative 
methods produce lists of molecules that differentiate disease states based on biofluid or 
tissue analysis. Mass spectrometry is the most common technique for unbiased discovery 
where all molecular components within the capability of the equipment and its algorithms 
are identified(Rifai, Gillette, & Carr, 2006). Microarray immunoassay techniques are 
more sensitive and specific in molecular identification, but they only measure the 
concentrations of a predetermined panel of molecules(Jastrow et al., 2009). Both 
techniques have benefits and drawbacks for clinical usage, particularly in the analysis of 
human serum(Hoofnagle & Wener, 2009). Qualitative methods produce lists of 
molecules, molecular interactions, and biological pathways gathered from published 
literature and databases; techniques include manual and automated text mining and 
network analyses to uncover disease associations(Yang, Adelstein, & Kassis, 2009; 
Yang, Pospisil, Iyer, Adelstein, & Kassis, 2008; Yanliang, Yang, & Min, 2009). Factors 
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relevant to quality molecular pattern discovery include minimization of restrictions on 
initial molecule identification; measurement of biofluids likely to have molecules with 
significant sensitivity and specificity to a disease; identification of patterns of molecules 
and molecular interactions based on the measured biofluids; use of bioinformatics to 
connect identified molecules with published literature and databases; and support of 
computationally tractable algorithms for discovery(Good et al., 2007; Lescuyer, 
Hochstrasser, & Rabilloud, 2007; Rifai et al., 2006).  
Abundance of quantitative molecular data. Rapid advances in lab technologies 
have made it easier and cheaper to measure vast quantities of molecular data in human 
blood and tissue. For example, multiplex molecular technologies now perform 
simultaneous measurements of millions of biological entities within the same assay. Not 
only is this faster than single measurements such as blots, performing the assays at the 
same time limits the environmental and operational variability that influences assay 
interpretation. The general public is now aware of the potential of molecular profiling. 
Early adopters can now contact the Biophysical Corporation in Austin, Texas for a 
$3,400 “biophysical” assay of more than 250 blood molecules considered to be 
“diagnostic biomarkers” associated with diseases or conditions(Biophysical, 2009).  
Microarrays are a well-known multiplex technology that has been at the leading edge 
of biomedicine since the 1990s. The term microarray was originally used for the 
miniature DNA microarrays that measure thousands of specific DNA sequences from 
biological samples on glass slide chips or nano-well arrays. DNA microarray technology 
has been applied in many areas such as gene expression profiling to find which genes 
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change expression in response to disease and to compare genomes in different 
organisms(Khan et al., 1999; Tintle et al., 2008).  
Next generation methods are manipulating and creating even more data: Illumina 
sequencing technology processes massively parallel sequencing of millions of DNA 
fragments(Illumina, 2009). The ability to simultaneously measure proteins, protein-
protein interactions and protein-DNA interactions in tissue and biofluids is increasing. 
Multiple expression levels of cytokines – signaling proteins that play important roles in 
cell physiology and pathology - can now be simultaneously determined using enzyme-
linked immunosorbent assay (ELISA)-based protein array technology. High density 
protein microarrays can now profile over 8000 proteins(Invitrogen, 2009).  
Automated techniques are speeding up the processing of molecular data while 
decreasing the expense. Immunohistochemistry (IHC) localizes proteins in cells of tissue 
sections to identify molecules associated with cellular pathways and functions. IHC is 
used extensively to evaluate cancerous tumors, and has been traditionally scored by 
fluorescent in-situ hybridization (FISH), a sensitive but slow, complex and costly 
cytogenetic technique. New scoring methods, such as the automated cellular imaging 
system ACIS™, are now proving to be faster, less expensive, reliable and as accurate as 
FISH(Tawfik et al., 2006). 
The technical ability to measure this deluge of quantitative molecular data is now 
about to move from the bioscience lab to clinical research for use in personalized 
medicine. For example, an integrated blood barcode assay chip is now in development for 
bedside use in clinical trials. It measures a large number of serum proteins within a few 
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minutes of a small sample(Fan et al., 2008). The challenge of new technologies is in 
understanding the biomedical significance of the huge amount of data generated(Hu, 
Coombes, Morris, & Baggerly, 2005; Rogers & Cambrosio, 2007). 
Abundance of qualitative pathway knowledge resources. In addition to the 
quantitative data now measurable, there is an ever-increasing amount of qualitative data 
about molecular interactions. From the mid 1980s through 2008, PubMed gained 30,000 
articles on signaling pathways and the advent of microarray technologies in the late 
1990s spurred on signaling pathway research. More than 10,000 of the 30,000 PubMed 
signaling pathway articles relate to human cancer(NLM, 2008a), 347 articles to trauma, 
and 26 to multiple organ failure(NLM, 2008b). The under-representation in the latter two 
categories may be due to the fact that cancer studies examine molecular pathways in 
excised tissue, whereas trauma studies measure initiator signaling molecules in biofluids 
and infer the signaling pathways on an experiment by experiment basis. 
Biological researchers, both experimental and theoretical, have organized the 
patterns of molecular interactions into spatio-temporal networks of pathways 
representative of cellular functions such as regulation of gene expression, metabolism and 
signaling(Slonim, 2002). Biological networks include measured molecules and 
interactions plus molecules and interactions inferred by computation or by similarities 
among organisms such as Saccharomyces cerevisiae, Escherichia coli, Rattus norvegicus, 
Mus musculus, and Homo sapiens.  
Signal transduction pathways represent the cascades of reactions within or between 
cells that mediate cellular processes. They are the primary communication channels 
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within the organism to regulate physiology(Pawson & Nash, 2000) and they are usually 
drawn as networks with molecules as nodes and molecular interactions as edges. Once a 
network is in graphical form, it can be analyzed using graph theoretical methods from 
computer science, matrix algebra, and other mathematical constructs. 
Signaling networks are inferred experimentally and / or computationally 
(Eungdamrong & Iyengar, 2004) from temporal and spatial patterns of molecules 
associated with specific intracellular functions such as apoptosis(Cho, Shin, Lee, & 
Wolkenhauer, 2003), gene activation and cell growth(Bhalla & Iyengar, 1999; 
Levchenko, 2003) or systemic functions such as inflammatory response(Calvano et al., 
2005; E. Lin, Calvano, & Lowry, 2000; Salomao et al., 2008).  
As technology advances, the ever-updated pathway information is disseminated 
through the internet, and there are numerous web-based commercial and academic 
knowledge bases of biological pathways. In 2001, only 18 pathway websites were 
active(Wixon, 2001). Today PathGuide.org references more than 290 pathway resources 
categorized by availability, data access methods, tools, organisms, network category, and 
contents. More than 30 million molecular interactions are accessible(PathGuide, 2010). 
The Pathway Database section of KEGG (Kyoto Encyclopedia of Genes and Genomes) 
includes networks relating to metabolism, genetic and environmental information 
processing, cellular processes, human diseases and drug development(KEGG, 2009). The 
Signal Transduction Knowledge Environment (STKE) lists 49 canonical pathways with 
1084 component molecules and 33 specific pathways (specific to a particular organism, 
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tissue, or cell type) with 718 components(STKE, 2009). There is an abundance of 
accessible resources on biological pathways.  
Problem Statement 
The general problem is that there has been a dearth of methods that support data-
driven, molecular based, clinical research in disease progression. First, patient molecular 
data is limited. There are usually few patients in a prospective observational non-cancer 
clinical study of disease progression. Measuring molecular patterns in bio-fluids or 
tissues is not a standard procedure in clinical care research, even in an Intensive Care 
Unit (ICU). This results in small sample sizes of patient data limited to non-parametric 
statistical analysis. Secondly, analysis methods for molecular patient data are uncommon, 
and time-oriented algorithms are even scarcer, as will be shown in Chapter 2. 
The question is how to use the limited temporal molecular patient data to add more 
information that is available, but not easily accessible, from biochemical resources in 
literature and databases, and then, how to analyze that combined, larger data set over time 
and other stratifications to analyze disease progression. The challenge with resources, 
such as databases of molecular interactions, is analyzing the spatiotemporal interplay of 
uncountable numbers of molecular interactions within each cell and across the 100 
trillion (1014) cells in the human body. 
The first step would be for research to uncover “gold standards” of molecular 
patterns associated with disease progression, followed by development of protocols and 
assays for bedside use.  
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The specific problem addressed by this study was how to connect quantitative 
spatiotemporal bioassay data of signaling molecules called cytokines with qualitative 
biological pathway information in order to uncover likely molecular patterns associated 
with systemic responses in disease progression.  
Signaling pathways are initiated by biological entities outside the cell and they 
control cellular functions including proliferation, apoptosis, and necrosis. Signaling 
pathway initiators include cytokines, hormones and growth factors in the blood, lymph or 
interstitial tissue and biomechanical stimuli like tissue strain(Knobloch, Madhavan, Nam, 
Agarwal, & Agarwal, 2008; Lucitti et al., 2007; Morrow et al., 2007). When signaling 
molecules travel through the body and meet matching receptors on a cell, the functions of 
the respective signaling pathways in that cell are activated, modulated, or inhibited. 
Because the measurable signaling initiators of the pathways appear before the 
inferred signaling pathway functions are executed, hypotheses can be generated to 
discover what this “advance notice” means – such as what are the underlying biological 
mechanisms or how treatment might direct the body system to mitigate pathways that go 
out-of-control.  For example, initiators of pathway cellular functions can make signaling 
pathways compete or cooperate to destroy malformed cells, or suppress that destruction, 
resulting in tumors that may be cancerous. In trauma, the initiators activate a pro-
inflammatory systemic response across many pathways to help the body fight immediate 
injury; however, if the “turn off” set of signals is not received in time by the pathways in 
the cells, the person can die. Since the initiators occur in the body ahead of the response, 
and initiating signaling molecules such as cytokines can be measured in serum, there 
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exists an “advance warning system.” Early knowledge of which pathways are active or 
inactive over time within a specific biological context can assist clinical decisions. This is 
of particular use in trauma where time is of the essence.  
Study Purpose, Scope and Deliverables 
The purpose of this study was to develop and document a computational method to 
support the research hypotheses that cellular functions are the foundation for 
physiological mechanisms, and that systemic patterns of measured molecules could be 
associated with larger biological pathways amenable to time-based analysis of disease 
progression.  
The method was named the Pathway Semantics Algorithm (PSA) because it analyzes 
the meaning of biological pathways within clinical contexts. PSA addresses the need for a 
computationally tractable methodology to connect quantitative molecular data with 
qualitative pathways. PSA was designed to support translational systems biology and 
enable dimensionality reduction of data, statistically guided pathway selection, 
comparison of pathways across clinical conditions and over time via matrix algebra, and 
generation of clinical/biological hypotheses for wet lab testing or clinical trials. PSA was 
applied to analyze systemic responses in two biomedical domains, and validated through 
literature, expert opinion, and experiment. 
Study Significance 
The capability exists today for generating large amounts of quantitative bioassay data 
for patients in a variety of clinical conditions such as critical care and cancer. 
Simultaneously, availability of qualitative information on biological pathways is rapidly 
9 
increasing. However, there is a dearth of methods that can effectively connect these two 
categories of data with a view to achieving a deeper understanding of the relationship 
between evoked pathways and concentrations of initiating bio-molecules. This 
information can yield valuable insights into underlying mechanisms of disease 
progression and help formulate therapy. 
The Pathway Semantics Algorithm, the subject of this research, is a step in this 
integrative direction, following the viewpoint expressed by Simon Rosenfeld of the 
National Cancer Institute that the first small steps toward translational systems biology 
models “should be in the direction of integration rather than towards further elaboration 
of individual processes and their in-depth mathematical modeling. In fact, the mass of the 
knowledge currently available is so monstrously huge that it may have already passed the 
point of being manageable. There is a serious risk of completely losing this knowledge 
for any practical purpose unless decisive steps towards integration are 
undertaken.”(Rosenfeld & Kapetanovic, 2008) 
In chapter 2, the literature review confirmed that there are a limited number of 
computational methods available for translational clinical research. One of the challenges 
is the development of new methods based on theoretically sound and computationally 
tractable techniques that can be scaled to an organism level.  
The potential significance of this study is that it adds a novel methodology called the 
Pathway Semantics Algorithm (PSA) that addresses these needs. In contrast to other 
graph/matrix systems biology tools, PSA compares networks of patient data-driven 
biological pathways over time or other stratifications at the organism level. Temporal 
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analysis is important and the time factor has been recognized as important in the 
specificity of signaling pathways(De Meyts et al., 1995). However, time-based pathway 
models at the molecular level generally consist of sets of differential equations with 
assumed kinetic constants that are computationally intractable at the organism level. PSA 
overcomes this limitation. 
The methodology appears to be repeatable, generalizable, scalable and extendable. 
PSA expands patient data by incorporating biological pathway data into the mix, and then 
facilitates analysis of that data over time and other stratifications using numerical linear 
algebra to generate useful hypotheses that answer biological questions. PSA algebraically 
post-processes evoked pathway networks to reveal changing molecular patterns not easily 
observed in the static text and graphical formats output by biological pathway generation 
programs such as Ingenuity Pathway Analysis (www.ingenuity.com). The algebraic post-
processing changes the data representation; this is important because the data 
representation space is one of the four inter-related problem spaces in scientific 
discovery, along with the hypothesis space, the experiment space, and the experimental 
paradigm. Changes in data representation uncover regularities and invariants, facilitate 
categorization, and suggest alternative search strategies key to scientific 
discovery(Schunn & Klahr, 1995).  
PSA differs from graphical analysis since it does not start with predetermined graphs 
of canonical pathways. PSA starts with clinical data upon which biological pathway 
networks are constructed based on most likely interactions even if they are not part of 
canonical pathways. Finally, PSA uses mathematical algorithms for matrix representation 
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and computation that are readily available and can be implemented in a wide variety of 
software. A key advantage of PSA is that it narrows down the potential hypotheses for 
further investigation, thus reducing costly lab and clinical research efforts. 
PSA can benefit clinical practice because it shows how the fundamental mathematics 
of numerical linear algebra can be used in a novel manner for comparative analysis of 
biological pathways in disease progression. Simple computations can be performed using 
spreadsheet calculations familiar to clinicians; more complex work for specific clinical 
contexts can be developed into software. Finally, PSA can benefit future research because 
it is a fundamental method that is adaptable to a wide range of studies on disease 
progression or comparison. 
Theoretical / conceptual framework 
The theoretical substruction map(Dulock & Holzemer, 1991; Hinshaw, 1979; 
McQuiston & Campbell, 1997; Trego, 2009; Wolf & Heinzer, 1999) for the research 
project is given in the Appendix, illustrating the linkages from the source study fields 
used through to the data analysis performed. The framework is as follows. 
Study fields. The project draws on work in the fields of systems biology and clinical 
research. 
Theories. From systems biology come theories of molecular interactions and 
algebraic analysis of networks. From clinical research come theories of disease 
progression. 
Models. Models used include network representation of biological interactions, 
matrix representation of a network, and models of inflammatory and immune response. 
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Concepts. The major concepts included are molecular interactions, directed graphs, 
molecules, matrix algebra, changing patterns of molecules over time, and measures of 
disease progression. 
Aims. The specific aims of the project were to:  
• develop the PSA method for node analysis and edge analysis,  
• apply PSA to a study of multiple organ failure in shock / trauma and to a study of 
immune response in hemophilia A, and  
• validate PSA through literature search, expert opinion, and, if feasible, laboratory 
experiment. 
Research questions. The research questions for each application were: 
• Which molecules differentiate disease progression? 
• Which molecular interactions differentiate disease progression? 
Variables. Variables included measured molecules, inferred molecules, inferred 
molecular interactions, time, clinical outcomes or treatment effects. 
Operational definitions. 
• Measured molecules: cytokines 
• Inferred molecules: genes, proteins, chemicals 
• Inferred molecular interactions: molecule to molecule interactions 
• Time: time in periods of hours or elapsed time in days 
• Outcome: multiple organ failure or not 
• Treatment effect: PBS versus CFA/I 
13 
Data analysis. Cytokines were measured in pg/ml. Inferred molecules and molecular 
interactions were obtained from a pathway database based on the cytokine measures. 
Time was measured in hours or days. The analysis was done on the stratification of 
outcome or treatment effect.  
Summary 
To date there appears to be no generalizible, computable systems-level methods that 
utilize spatiotemporal bioassay data to answer biomedical questions arising from 
comparative analysis of biological pathways. However, there is a need to connect 
bioassay data with pathway information within specific biomedical contexts and to 
facilitate comparison of biological pathways by time, outcome, molecular location and/or 
cell cycle phase. If these needs could be met, clinical research could start utilizing the 
wealth of constantly updated biological pathway information on a regular basis, and 
generate baseline hypotheses for mechanisms and recommended therapy – and keep a 
few steps ahead of the molecular data deluge that is about to impact clinical medicine.   
The overarching goal of the Pathway Semantics Algorithm is to improve the in silico 
identification of clinically useful hypotheses about molecular patterns in disease 
progression. By framing biomedical questions within a variety of matrix representations, 
PSA has the flexibility to analyze combined quantitative and qualitative data over a wide 
range of stratifications. The resulting hypothetical answers can then move to in vitro and 
in vivo verification, research assay optimization, clinical validation, and 
commercialization. Herein PSA is shown to generate novel hypotheses about the 
significant biological pathways in two disease domains: shock / trauma and hemophilia 
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A, and validated experimentally in the latter. The PSA matrix algebra approach identified 
differential molecular patterns in biological networks over time and outcome that would 
not be easily found through direct assays, literature or database searches.  
The next chapter is a literature review of relevant computational methods. Chapters 3 
and 4 describe PSA for node and edge analysis respectively, and apply the method to 
disease progression in shock / trauma. Chapter 5 demonstrates the application of PSA to 
hemophilia A and the validation with experimental results. The work is summarized in 
Chapter 6, followed by extensive references and an Appendix with additional material. 
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Chapter 2 Literature Survey 
This chapter presents a survey of computational tools, techniques, and resources 
from systems biology that can be used to increase understanding of the physiological 
mechanisms in disease progression. The intention is to show data processing and analysis 
methods that may be adaptable from the molecular and cellular levels to investigations at 
the tissue, organ, and whole body system levels, highlighting common processes and 
procedures that may be useful for investigative studies and personalized medicine. The 
scope of this chapter is limited to resources for potential applications in shock trauma and 
critical care; however, the underlying methods may be useful in a wide range of 
translational clinical research in disease progression.  
It is my contention that systems methods can assist in the identification of 
measurable characteristics in critically injured trauma patients that point to underlying 
disrupted biological mechanisms that may be amenable to treatment with a resultant 
increase in survival(Karvunidis, Mares, Thongboonkerd, & Matejovic, 2009; Neugebauer 
& Tjardes, 2004; Polpitiya, McDunn, Burykin, Ghosh, & Cobb, 2009; Vodovotz, Csete, 
Bartels, Chang, & An, 2008). The challenge is that systems biology analyzes physiology 
from the “bottom-up”, modeling molecules, organelles, and biological pathways within 
cells whereas clinical medicine treats a patient from the “top-down”, evaluating the 
whole body, based on observable measures from biofluids, tissues, and organs. The data 
from both extremes vary considerably over scales of time and space. For example, data 
can be baseline, measured at specific intervals, or measured continuously. Data can be 
numbers, words or patterns describing serum protein concentrations or heart rates.  
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There are vast databases with biochemical data and computational models that can 
offer insights into disease progression, if they can be linked to specific patterns of patient 
characteristics and if clinicians were enabled to judge clinically relevant factors that arose 
from systems biology. Specific treatments based on an individual’s underlying 
physiology, in addition to phenotype(Butte, 2008; Hofer et al., 2009; Salluh & Bozza, 
2008), are important in the development of personalized therapies. Clearly a two-stage 
translational approach is required: first, clinical researchers need to identify “gold 
standard” data patterns that include measurable biochemical data associated with 
prognosis, diagnosis or treatment. Secondly, protocols and parameters that incorporate 
this information must be developed for clinical use. In both stages, computational 
methods are needed: first for discovery of likely biochemical patterns and disease 
associations, and secondly, to provide patient data-driven reports that include systems 
information to assist clinicians in assessing and directing patient care.  
 Because ICUs are already prepared to monitor and collect massive amounts of 
temporal physiological and clinical data, they are a likely candidate location for studies 
and applications of translational systems biology. In this chapter, I present a selection of 
recent approaches and their application to research in biological processes in trauma and 
critical care, such as inflammatory, immune and injury responses. The emphasis is on 
computational methods that can be used for data-driven systems analysis of disease 
progression. 
In the following section, I give a short overview of systems analysis and systems 
biology, approaches used in trauma research, and data available. In Section 3 
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computational methods are discussed, followed by Section 4 with selected applications. 
The literature review is summarized in Section 5.  
Systems Analysis and Systems Biology 
Systems analysis is “a method of describing and understanding complex interactions 
among large numbers of processes or components in a generalized way. The focus is on 
identifying the fundamental units of a system and defining how they interact rather than 
the internal processes of each unit”(Aber & Melillo, 2001; Yourdon, 1988). Systems 
analysis can be performed to generate or test hypotheses about the systems behavior 
within specific assumptions and constraints. Analysis techniques may be qualitative or 
quantitative, static or dynamic, stochastic or deterministic, or combinations. The 
fundamental units (components or processes) may be nested within a hierarchy or 
overlapping.  
Systems biology, a subcategory of computational biology, is defined by the National 
Library of Medicine (NLM) as the “comprehensive, methodical analysis of complex 
biological systems by monitoring responses to perturbations of biological processes and 
using the large scale, computerized collection and analysis of the data to develop and test 
models of biological systems”(NLM, 2009). From its beginnings, systems biology aimed 
at building mathematical frameworks with some predictive abilities based on systematic 
organization of genomic and proteomic data(Aggarwal & Lee, 2003). Since then, the 
scope of systems biology has expanded and spawned a number of related offshoots such 
as translational research(NIH, 2009), translational systems biology(G. An, Faeder, & 
Vodovotz, 2008), translational bioinformatics(AMIA, 2006), and systems 
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medicine(Clermont, Auffray, Moreau, Rocke, Delavi et al., 2009; Clermont, Auffray, 
Moreau, Rocke, Dalevi et al., 2009). Although analysis goals, abstraction levels, and 
scales vary widely, the fundamental units under study are usually molecules, cells, 
tissues, organs, and organisms within a hierarchical framework with modular control 
elements or related biological processes(G. C. An, 2010; M S Iyengar, Brown, & 
McGuire, 2007; Lauffenburger, 2000; Malhotra et al., 2008). 
Systems approaches in trauma  
Trauma refers to serious bodily injury, which, if of sufficient magnitude, may be 
accompanied by initiation of the systemic inflammatory response. Causes of trauma 
include penetrating injuries from gunshots and stab wounds, blunt injuries, such as those 
sustained during automotive accidents, and burns. In addition to direct tissue damage, 
trauma can result in injury to remote organs due to disruptions in normal physiology and 
underlying protective biological mechanisms. These remote injuries can be rapid in onset 
and potentially fatal if allowed to proceed unabated. Moreover, trauma is the leading 
cause of mortality in the US among individuals under 45 years of age, and the cause of 
death for 74% of all deaths for people ages 15-24(Heron, Hoyert, Xu, Scott, & Tejada-
Vera, 2008). In critically ill patients, normal biological processes are disrupted but the 
associated pathophysiology is incompletely understood(Deitch, 1992; Maier et al., 2007; 
Wan et al., 2008). 
Within the past decade, a number of systems approaches for analysis of trauma and 
critical illness have been developed(Buchman, 2009; Vodovotz et al., 2007). 
Computational methods have been used to increase understanding of systemic functions 
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such as inflammation and immune response(G. An, 2001; Dong, Foteinou, Calvano, 
Lowry, & Androulakis, 2010; N. Y. Li et al., 2008; Ta'asan & Gandlin, 2009; Vasilescu, 
Buttenschoen, Olteanu, & Flondor, 2007; Vodovotz et al., 2009)and the effects of drug 
dosing(Yamamura et al., 2004), as well as organ specific issues such as heart rate 
complexity(Cancio et al., 2008; Riordan, Norris, Jenkins, & Morris, 2009)and acute lung 
injury(Ware et al., 2009). Multiscale computational models of angiogenesis, from the 
molecular to the organ system levels, have been integrated to improve predictive 
capabilities(Qutub, Mac Gabhann, Karagiannis, Vempati, & Popel, 2009). At the 
molecular/cellular systems level, there are numerous computational approaches in 
systems biology used to study biological mechanisms such as signaling(Rangamani & 
Iyengar, 2008), metabolism(Palsson, Joshi, & Ozturk, 1987), and protein interactions(C. 
Y. Lin et al., 2008)that underlie disease progression. With the advent of new technologies 
that make it feasible – and soon cost-effective – to capture patient’s molecular data such 
as mRNA expression or serum protein concentrations, translational clinical research can 
benefit from using computational approaches beyond classical statistical inference. A 
systems-wide analysis of data from the molecular to the organism level can help design 
evidence-based personalized therapies. 
Data for systems approaches in trauma  
The complex and often rapid progressions of shock trauma and critical illness 
provide a vast quantity of patient data that can be collected and evaluated through real-
time monitoring in an intensive care unit (ICU) on a continuous, hourly, or daily basis. 
Intensive care units collect one item of documented clinical information per patient each 
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minute(Manor-Shulman, Beyene, Frndova, & Parshuram, 2008). In addition to monitored 
data, patient data includes transfusion and drug orders, microscopy, radiology and 
laboratory reports, nursing and clinician notes, and patient demographics. As bedside 
biofluid measurement devices move from prototype to practicality(Fan et al., 2008; 
Sorger, 2008), a patient’s molecular data such as serum proteins can also be collected in 
time to be of use in the ICU; currently, turnaround time for molecular assays is not 
practical for other than research use. The challenge today is to understand the meaning of 
all this data in terms of disease progression, and develop data-driven protocols that will 
be in place when the technology is available. For example, research has shown that 
specific patterns of cytokine molecules over time are associated with trauma 
progression(Jastrow et al., 2009; Maier et al., 2007; Roumen et al., 1993). Cascade 
patterns of molecular interactions, such as those triggered by cytokines, have been 
identified as biological pathways – spatiotemporal networks representative of cellular 
functions that regulate gene expression, metabolism and signaling(Slonim, 2002). 
Because cytokines drive signaling in biological pathways, adding cytokine data may 
provide insight into the underlying biological mechanisms.  
There are an ever-increasing number of databases with information about biological 
pathways. In 2001, only 18 pathway websites were active(Wixon, 2001). Today, 
PathGuide.org references more than 290 pathway resources categorized by availability, 
data access methods, tools, organisms, network category, and contents. More than 30 
million molecular interactions are accessible via the Internet(PathGuide, 2010). The 
Pathway Database section of KEGG (Kyoto Encyclopedia of Genes and Genomes) 
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includes networks relating to metabolism, genetic and environmental information 
processing, cellular processes, human diseases and drug development(KEGG, 2009). 
More than 1400 curated, experimentally determined, metabolic pathways and enzyme 
data for microbial, plant, and vertebrate metabolism are available from the freely 
accessible MetaCyc database(Caspi et al., 2010). There are commercial and publicly 
available databases of molecular interactions(Tarcea et al., 2009), biological 
pathways(Elliott et al., 2008; Visvanathan et al., 2008; Wixon, 2001), and genomic 
correlates(L. T. Sam et al., 2009). The Signal Transduction Knowledge Environment 
(STKE) lists 49 canonical pathways with 1084 component molecules and 33 pathways 
specific to a particular organism, tissue, or cell type with 718 components(STKE, 2009). 
PubMed lists more than 250,000 articles with content about signal transduction pathways; 
the earliest articles are from 1947 – before systems biology as such existed(Baumgardt, 
1947; Berliner, 1947; Monnier & Boehm, 1947).  
The question is how to integrate all this data? One approach is to use computational 
methods from systems biology to connect patient data with data from basic science 
resources in biology, chemistry and physics to develop research models that can 
transition to data-driven clinical practice. See Figure 2-1. Even with computational 
approaches, the data translations and transformations among levels from molecule to 
organism and vice-versa are far from seamless. Most applications cobble together several 
methods to achieve their research goals. In the next section, I review some of the major 
computational methods that have been used to analyze biological processes related to 
trauma and critical illness; this is followed by Section 4, giving details of several 
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applications. The intent is to inspire creative use of methods and data in the investigation 
of trauma and critical illness, with the goal of improving patient care.  
 
 
Computational Methods 
The biological processes in shock trauma and critical illness are complex and 
unstable. There are simultaneous and rapid changes of biological pathways across and 
within the entire body. Extracellular and intracellular signaling modulates systems-wide 
mechanisms such as inflammatory response(Levi, Keller, Van Gorp, & Ten Cate, 2003; 
Pillay, Hietbrink, Koenderman, & Leenen, 2007; Rezende-Neto et al., 2002), sepsis, 
hemorrhagic shock, and resuscitation from hemorrhagic shock(Rittirsch, Flierl, & Ward, 
 
 
 
Figure 2-1 Computational methods integrate translational research 
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2008; Tracey, 2007; Webster & Galley, 2009). The choice of systems analysis and 
computational methods depends on several factors: 
• The systems level(s) under study, from molecule to organism;  
• The available data; and 
• Which biological processes are under study, within what context, and for 
what goals.  
Hypotheses about disease progression can be generated computationally in many 
ways:  from data-driven model-free discovery to the perturbation of in silico models of 
biological processes. This section is an overview of common computational methods in 
use plus some general considerations for data; selected applications related to trauma and 
critical care will be shown in Section 4. Here I first present basic probabilistic and 
deterministic approaches that utilize a wide variety of fundamental tools and techniques 
that can be used individually, combined, or in combination with other methods. This is 
followed by a selection of more specialized methods.  
Basic probabilistic approaches 
Classical Statistical Inference incorporates no prior information and assumes 
independent variables; the approach is used at all systems levels and underlies the 
primary tools, such as Student’s t test, used for static analysis of injury response where 
there is sufficient data. In contrast, Bayesian Statistical Inference incorporates prior 
information and handles interdependent variables. The Bayesian “conditional 
probability” approach is becoming more and more widely used in genetic data 
analysis(Beaumont & Rannala, 2004), clinical research(Moyé, 2008) and diagnostic 
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medicine; complex Bayesian analyses are usually performed using Markov Chain Monte 
Carlo (MCMC) computational methods(Broemeling, 2007). MCMC methods use Monte 
Carlo random sampling to produce a Markov Chain with state transitions that converge to 
an invariant distribution. A Markov Chain is the simplest autonomous form of a discrete-
time probabilistic state-transition Markov model where the system state is observable. 
Common statistical software includes R (www.r-project.org), Spotfire S+ 
(http://spotfire.tibco.com/products/s-plus/statistical-analysis-software.aspx), SPSS 
(www.spss.com), and SAS (www.sas.com). OpenBUGS is open-source software for 
Bayesian analysis using MCMC methods (www.openbugs.info/w).  
Basic deterministic approaches 
Deterministic approaches depend on initial states and chosen parameters. Differential 
equations are the primary methods of deterministic dynamic analysis, and are mostly 
used at the molecular and cellular levels because they are computationally intensive at 
higher levels. For example, modeling one NFκB signaling pathway in one cell activated 
by one signaling TNF-α molecule requires 18 nonlinear differential equations, with 33 
independent variables and 16 dependent variables in a simplified reaction kinetics 
model(Cho et al., 2003); scaling this method directly to the organism level is 
computationally intractable. Ordinary differential equations (ODEs) model dynamic 
changes in items, such as protein concentrations, over one independent variable whereas 
partial differential equations model simultaneous changes over two or more independent 
variables. Explicit equations are used, usually with equilibria or other constraint 
assumptions. In addition to experimental data, the equations require data for estimated 
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biochemical kinetic parameters, which are usually inferred from published results. 
Differential equations can be solved using standard mathematical software available as 
open source or commercial software such as MATLAB(MathWorks, 2010) and 
Mathematica(Wolfram, 2010).  
Matrix algebra can be applied from molecular to organism levels. Stoichiometric 
matrices are used for flux-balance analysis (FBA) of metabolic biochemical reaction 
networks(Palsson et al., 1987; Schilling & Palsson, 1998) to stochastically simulate 
chemical kinetics. Unlike differential equation approaches, FBA does not require reaction 
rate kinetic parameters or metabolite concentration data. Instead, the key assumptions are 
that the system is homeostatic with a balanced system of energy production and 
consumption and that the metabolites are “well stirred” so that Gillespie’s Algorithm can 
be used(Gillespie, 2008). This steady-state approximation of cellular dynamics can offer 
insights into multiscale snapshots of disease progression. Matrix algebra formalisms have 
been used to study signaling and regulatory pathways using extreme pathway analysis, an 
adaptation of the stoichiometric approach used for metabolic analysis(Gianchandani, 
Papin, Price, Joyce, & Palsson, 2006; Papin & Palsson, 2004) and to generate signaling 
networks from sparse time series of observed data(Allen et al., 2007). The latter 
computational algebra approach has potential for analysis of signaling pathways in 
disease progression.  
Matrix decomposition methods are the basis for a wide variety of factor and 
component analyses in data mining and graphical analyses(Skillicorn, 2007; Sun, Xie, 
Zhang, & Faloutsos, 2008). In addition to techniques such as singular value 
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decomposition (SVD), new matrix approaches are evolving such as the graph-
decorrelation algorthm (GraDe) that performs detailed temporal analyses on large-scale 
biological data using knowledge-based matrix factorization. In a recent time-course 
microarray experiment of mouse hepatocytes, GraDe provided a detailed separation of 
the time-dependent responses to IL-6 stimulation compared to standard 
methods(Kowarsch et al., 2010).  
Matrix algebra can be performed using software as simple as spreadsheets; more 
complex calculations use software such as MATLAB or Mathematica. Code for 
Gillespie’s Algorithm is available for R (http://cran.r-
project.org/web/packages/GillespieSSA/index.html) and for 
Mathematica(http://demonstrations.wolfram.com/DeterministicVersusStochasticChemica
lKinetics/). 
Graphical approaches 
Cascades of molecular interactions can be represented as directed graphs in order to 
use computational methods from graph theory to explore pathways within the graph. The 
analysis is usually at the molecular and cellular levels, although the methods can be 
adapted for higher levels. Biological pathways can be abstracted as network graphs with 
nodes representing molecules and edges being molecular interactions(Alon, 2007; 
Ma'ayan, 2008). Patterns of molecules, such as serum cytokines, have been associated 
with disease progression in trauma, and graph theory methods offer ways to analyze this 
data. Graph theory is supported by extensive computational methods from mathematics 
and computer science that are used for analysis of static and dynamic systems ranging 
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from computer systems to social networks. Structural properties of the graph can be 
measured in many ways such as counting the number of nodes and edges, number of 
edges per node or nodes per edge, identifying primary hubs and sub-network motifs. 
Computational methods are usually analysis specific. For example, the web-based Hub 
Objects Analyzer (Hubba-Hubba, http://hub.iis.sinica.edu.tw/Hubba/index.php) identifies 
essential hubs in a protein interaction network by using a combination of software 
including databases, graph generators, and topology calculators(C. Y. Lin et al., 2008).  
A Bayesian network is a probabilistic graphical model constructed as a directed 
acyclic graph (DAG) with nodes representing variables and edges representing the 
conditional dependencies between the nodes. Bayesian networks are used for process 
modeling and diagnostic reasoning(Darwiche, 2009; Koller & Friedman, 2009). One 
class of Bayesian networks is based on Hidden Markov Models (HMMs) - Markov 
Chains with hidden rather than visible states but with visible state-dependent outputs. 
HMMs can be used to uncover an optimal sequence of state transitions. One limitation of 
Bayesian networks is that they must satisfy the local Markov property - each node is 
conditionally independent of its non-descendents(Russell & Norvig, 2009); as a result, 
graphs with cycles are not supported. This limits modeling of biological pathways to 
small sections without loops. Recently, an extension to Bayesian network models, called 
Generalized Bayesian Networks (GBN), has been proposed that can model cyclic 
networks for use in translational systems biology(Sachs, Itani et al., 2009). There are a 
number of software packages for Bayesian networks including the Python library Pebl 
(http://code.google.com/p/pebl-project/) and Hugin (www.hugin.com).  
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Petri Net methods have been used to analyze Bayesian networks where the nodes are 
molecules and the edges represent the dependencies of the interactions between the 
nodes. Petri nets perform qualitative, stochastic and continuous analysis of small 
biochemical networks by modeling token-based transitions, such as reactions, between 
“places” such as proteins. Dynamic modeling is performed by incorporating differential 
equations to assign rate functions to transitions(Heiner, Donaldson, & Gilbert, 2010 ). 
Petri Net Toolboxes are available for MATLAB and Mathematica, and systems biology-
oriented Petri Net software called Snoopy is freely available (http://www-
dssz.informatik.tu-cottbus.de/snoopy.html; www.informatik.uni-
hamburg.de/TGI/PetriNets).  
Finally, Spectral Graph Theory incorporates both graph theory and matrix algebra to 
examine a network in terms of the eigenvalues and eigenvectors (spectrum) of the 
adjacency matrix mapped from the network graph(Cvetković, Doob, Sachs, & Torgasev, 
1988). This method has been used to compare basic metabolic networks at the systems 
level in three organisms Mycobacterium tuberculosis, Mycobacterium leprae and 
Escherichia coli. The results found that the most highly connected biochemical reactions 
in an organism are not necessarily those most central to the organism’s metabolism, 
suggesting that hubs present in mycobacterial networks that are absent in the human 
metabolome may be potential drug targets(Verkhedkar, Raman, Chandra, & 
Vishveshwara, 2007).    
Pathway databases use graph theory with published biological pathway data and 
proprietary computational network analysis algorithms to generate specific biological 
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pathways. For example, Biobase (BIOBASE GmbH, Germany; www.biobase-
international.com) has a data analysis system called ExPlain, and the Ingenuity 
Knowledge Base (Ingenuity Systems, US; www.ingenuity.com) supports Ingenuity 
Pathway Analysis. Advantages of these combined database / algorithm systems are that 
the pathway / molecular interaction data are kept up-to-date, and that the algorithm is 
specifically designed to work well with the database to uncover the pathways associated 
with the input data. Although this is advantageous for the general user, it must be noted 
that the underlying computational methods are not amenable to modification because 
they are usually based on proprietary algorithms with limited documentation. In addition, 
access to commercial web-based pathway databases and their analysis software is by paid 
subscription. 
Symbolic approaches 
Symbolic logic is a formal qualitative modeling approach used to answer questions at 
various levels of abstraction. The questions usually focus on a specific intracellular 
function such as signaling and a model is created based on system states and rules for 
state changes. Symbolic models can be analyzed or run as simulations; models can be 
formally checked and verified. A wide variety of computational methods for symbolic 
systems biology have been developed(M. S.  Iyengar, 2010 ). There are several 
implementations of rule-based modeling for signaling networks(Hlavacek et al., 2006) 
such as Pathway Logic, a symbolic rewriting logic based on pi-calculus(Knapp et al., 
2005; Talcott, 2006). 
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Artificial Neural Networks (ANN) and Agent-Based Models (ABM) 
ANN and ABM methods are used with organism-level data. However, both are 
computationally intensive and may require specialized software along with 
multiprocessor hardware. The artificial neural network (ANN) is a computational method 
to uncover nonlinear patterns based on input data. Several ANN models are generated 
from the training input data, and the one with the best fit between predicted and observed 
values is considered the optimal ANN model to be used for the actual data and 
predictions. Optimization techniques, such as the conjugate gradient decent 
method(Fletcher, 2000; Mary F.  McGuire & Wolfe, 1973), may be used to optimize the 
model. Nonlinear ANN modeling has been shown to be comparable to linear logistic 
regression analyses when sample size is adequate. However, it has been shown that 
training sets for ANN need at least 800 observations to generate an adequate model – a 
sample size not usually found in ICU trauma / critical care studies(Clermont, Angus, 
DiRusso, Griffin, & Linde-Zwirble, 2001). Standard mathematical and statistical 
software including MATLAB, Mathematica, SPSS and SAS have built-in algorithms or 
add-on modules for neural network analysis and optimization.  
Agent based simulation consists of an agent-based model (ABM) composed of 
autonomous fundamental units, or agents, defined at multiple scales or levels within a 
system and the rules that govern the state change interactions among them. The rules may 
be deterministic or stochastic. No explicit equations are used and there are no equilibria 
assumptions as in most models. The goal is to predict patterns of emergent behaviors that 
arise in complex systems from simple rules(G. C. An, 2010). The model must be verified 
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and validated in some way; simulations must be run many times to uncover relevant 
patterns. Two open-source software packages for ABM development are 
NetLogo(Wilensky, 2010)and SeSAm(Würzburg, 2010 ). FLAME (Flexible Large-Scale 
Agent Modelling Environment, www.flame.ac.uk)(Coakley, 2007; Richmond, Walker, 
Coakley, & Romano, 2010) is a formal framework that allows a wide range of agent and 
non-agent models to work together within one simulation environment. 
Applications 
In this section, I describe computational approaches currently used, or that have the 
potential for use, in critical care and trauma-related research. The applications are 
organized by research goals at levels from the organism level down to the 
cellular/molecular level. A short paragraph summarizes the goal, processes and context 
for the example, followed by a list of the methods and data used. See Figure 2-2. 
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Figure 2-2 Computational analysis at different levels within an organism 
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Organism level  
The organism level includes research performed at the molecular or cellular levels 
that investigates systemic processes such as inflammation, immune and injury responses. 
In the next two subsections, I show example of process models and predictive models. 
Organism level: Process models 
The inflammatory process is a normal physiological response in acute and chronic 
disease, and part of the immune response to infection. However, despite numerous 
computational models, much work still needs to be done to automate integration of these 
models with data across system levels with software usable by non-
mathematicians(Vodovotz et al., 2009). 
Abstraction. One of the earliest agent based models was developed by An(G. An, 
2001) to create a simple abstraction to simulate the nonlinear behavior and dynamic 
structure of the inflammatory response. Although the model was based at the cellular 
level, the abstraction was used for inference of the systemic response at the organism 
level. 
• Method: Agent Based Model using StarLogo software. (StarLogo is now 
available as open source OpenStarLogo at http://education.mit.edu/starlogo/) 
• Data: Abstractions of three cell types used as agents: endothelial cells (with injury 
states), neutrophils, and circulating mononuclear cells, plus rules for agent 
interactions. 
Challenge / Response. Endotoxin (LPS) and other challenges have long been used 
in shock trauma research(Foteinou, Calvano, Lowry, & Androulakis, 2008; Waage, 
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Brandtzaeg, Halstensen, Kierulf, & Espevik, 1989; Webster & Galley, 2009) to probe 
challenge/response relationships. 
Dong(Dong et al., 2010) created an agent based simulation to model the host 
response to endotoxin using the molecular interactions involved in the NFκB signaling 
pathway, coupled with the spatial orientation of various inflammation specific molecules 
and cell populations such as macrophages and T-helper cells.  
• Method: Agent Based Model using NetLogo software 
(http://ccl.northwestern.edu/netlogo/) 
• Data: Gene expression data from human subjects injected with endotoxin or a 
placebo. Biological data for agents (macrophages, cells and molecules) and agent 
rules (interaction behavior and rates). 
In contrast, Vasilescu(Vasilescu et al., 2007) developed an equation based model to 
evaluate whether endotoxin (LPS) tolerance is a component of the immune dysregulation 
in patients with trauma, severe acute pancreatitis, and diffuse peritonitis. 
• Method: Differential equations 
• Data: Endotoxin levels, TNF-α plasma levels, and TNF-α releasing capacity of 
the whole blood in patients with severe acute pancreatitis, diffuse peritonitis, and 
trauma. 
Muller(Muller & Tjardes, 2003) found bistability in the early inflammatory response 
by using an in vitro model of IL-1 challenge to derive an equation based in vivo model. 
The in vitro model was first developed by challenging endothelial cells with IL-1; then, 
the expected value of IL-6 at a specific time under a specific challenge was derived. The 
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basic mechanism of the in vitro model was expanded to a whole animal IL-1 challenge 
that modeled in vivo multistate inflammatory response. Of interest was the outcome that a 
small challenge did not lead to a response; however, a challenge above a certain threshold 
completely activated the endothelial cells.  
• Method: Differential equations 
• Data: IL-1 challenge levels and resulting IL-6 production levels in endothelial 
cells over time scales of minutes, hours and days. 
Guthke(Guthke, Moller, Hoffmann, Thies, & Topfer, 2005) generated plausible 
models of the gene regulatory networks involved in the human peripheral blood 
mononuclear cells’ immune response to an Escherichia coli infection challenge. The 
immune interaction networks were reconstructed by reverse engineering. First, a 
statistical cluster analysis of the scaled time profiles of the gene expression data was 
performed using the fuzzy C-means (FCM) algorithm(Bezdek, Keller, Krisnapuram, & 
Pal, 2005), and then expression profiles of the representative genes were used to drive 
three dynamic models of gene regulatory networks based on linear differential equations, 
systems of linear algebraic equations, or heuristic search strategies.  
• Method: Statistics, differential equations, linear algebra, heuristic search 
• Data: Log-ratios of the expression intensities of more than 18,000 genes in 
peripheral blood mononuclear cells at five time points before and after infection 
by heat-killed pathogenic Escherichia coli. 
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Organism level: Predictive models 
Probabilistic methods are used extensively in clinical research. Among the more 
common algorithms are the parametric Student’s t test for normally distributed 
quantitative variables, the non-parametric Mann-Whitney test for quantitative variables 
without a normal distribution, and chi-square tests for qualitative variables. For example, 
these methods were used by Pidcoke(Pidcoke et al., 2007) to demonstrate that the diurnal 
patterns of blood glucose and insulin requirements in burn ICU patients are similar to 
those in healthy subjects. 
• Method: Means, frequency analysis, simple and cosine regressions, Student’s t 
test, Mann-Whitney test, chi-square test 
• Data: From 156 burn patients: total body surface area burned, injury severity 
score, polytrauma, age, gender, inhalation injury, glucose level (hourly), insulin 
dose (hourly), outcomes. 
Cohen(Cohen et al., 2010) used hierarchical clustering to identify patterns of 
patients’ changing physiological states that were predictive of infection, multiple organ 
failure and mortality. Clustering is a multidimensional analysis that identifies groups of 
similar variables, with the results displayed as a dendogram tree structure. Limitations are 
that a variable may belong to only one cluster group, and the number of clusters may 
influence the result. 
• Method: Hierarchical clustering, linear discriminant analysis, correlations  
• Data: 45 measures of physiological, clinical, and treatment data were collected 
every minute from each of 17 severely injured trauma patients. Data for the 
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cluster analysis: continuous heart monitor, ventilator, and microdialysis data over 
24–72 hours (52,000 data points).  
Using a classical statistical model, Ware(Ware et al., 2009) identified a combination 
of biologic and clinical markers in patient data that predicted acute lung injury and acute 
respiratory distress syndrome. 
• Method: Wilcoxon rank sum test for continuous variables. Fisher’s exact test for 
categorical variables. Spearman rank correlation coefficient. Receiver Operator 
Curves (ROCs). Odds ratios.  
• Data: Retrospective study from NHLBI ARDS randomized controlled trial: 
patient baseline plasma measures of IL-6, IL-8, TNFR1, von Willebrand factor, 
surfactant protein D, sICAM-1, PAI-1, protein C plus baseline clinical variables 
such as age, cause of ALI/ARDS and APACHE III scores. 
In contrast, Peelen(Peelen et al., 2010) constructed three Markov models based on 
clinical data to gain insights into the probabilistic state transitions in organ failure 
progression in successive days of ICU stay. Peelen’s models identified potential clinical 
patient states (number and type of failing organ systems) along with the probabilities that 
each state would be followed by another state, or persist over time.  
• Method: Markov models with dimensionality reduction via additive logistic 
regression; implementation by hierarchical dynamic Bayesian networks; followed 
by stochastic simulations.  
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• Data: Temporal clinical data from a prospective study of severe sepsis patients. 
Patient data included SOFA scores per each of six organ systems plus total SOFA 
scores.  
Artificial neural networks (ANNs) were constructed by Yamamura(Yamamura et al., 
2004) to predict the plasma concentration of Arbekacin sulfate, an aminoglycoside, in 
burn patients and, from that prediction, identify patients whose Arbekacin sulfate 
antibiotic would be sub-therapeutic based on the patients’ physiological data. ANN 
results were superior to multivariate logistic regression analysis in classifying patients’ 
outcomes. 
• Method: Three-layered ANN model (Statistica software, www.statsoft.com). 
Conjugate gradient decent method for optimization during ANN training with 
training data. Leave-one-out cross-validation of predictive performance with test 
data. Multivariate logistic regression analysis (SPSS, JMP(SAS) and Statistica 
software). 
• Data: Clinical physiological data from 30 burn patients, plus data for assessing 
burn severity. Training data for ANN model: dose, body mass index (BMI), 
parenteral fluid, creatinine concentration and burn severity parameters.  
Organ level  
Heart. Using Multiscale Entropy (MSE) to assess Heart Rate Complexity (HRC), 
Riordan(Riordan et al., 2009) found that early loss of HRC was predictive of mortality 
regardless of anatomic location, severity or mechanism of injury.  
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• Method: HRC assessed by Multiscale Entropy (MSE)(Costa, Goldberger, & Peng, 
2005). Statistics (R software): Fisher’s exact test, Wilcoxon’s Rank Sum test, 
Kruskal-Wallis test, logistic regression, odds ratios, Receiver Operator Curves 
(ROCs). 
• Data: MSE; continuous physiological data from the first available 6 hours plus 
clinical data and demographics from 2718 trauma patients.  
Although HRC seems to be a useful mortality predictor in trauma, most HRC 
measures require a traditional 800-beat data set. In an emergency situation, such as a 
battlefield, this large amount of data presents a monitoring challenge. Using three entropy 
measures with data sets as small as 100 beats to assess HRC, Batchinsky(Batchinsky et 
al., 2009) found that HRC was decreased in pre-hospital trauma patients who died.  
• Method: HRC assessed by approximate entropy, sample entropy and similarity of 
distributions. Statistics (SAS): Student’s t test, Mann-Whitney U test, logistic 
regression, Receiver Operator Curves (ROCs), odds ratios, maximum likelihood, 
Pearson chi-square. 
• Data: EKGs with 800 RRIs from 31 pre-hospital trauma patients, with data sets 
sampled at 800, 600, 400, 200, and 100-beat data sets. 
Brain. Numerous computational models have been developed to increase 
understanding of traumatic brain injury resulting from blast survivability in war zones 
with the goal of improving design of personal protective equipment. Moore(D. F. Moore 
et al., 2009) used equation based models to study the effects of primary blasts on the 
central nervous system, and found that blast waves directly propagate into the brain and 
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that stresses develop in central nervous system tissues comparable to those significant in 
mTBI or concussive injuries in sports.  
• Method: Blast-solid interaction simulation of a full head mesh, with mesh 
generated from nonlinear partial differential equations in computational fluid 
mechanics software (ICEMCFD, www.ansys.com/products/icemcfd-mesh-
gen.asp) and brain tissue modeled by nonlinear algebraic equations of state. 
• Data: Peak blasts at two pressure levels; impact deceleration. High-resolution T1 
MR images. 
Tissue level  
Adra(Adra, Sun, MacNeil, Holcombe, & Smallwood, 2010) developed a multiscale 
3D model of the human epidermis to explore the functions of TGF-β1, a potent growth 
factor, during epidermal wound healing. A computational virtual epidermis was created 
using an integrated agent/COPASI model, followed by investigation of several 
hypotheses, including the changes in epidermal wound healing associated with different 
wound sizes.  
• Method: COPASI (COmplex PAthway SImulator)(Hoops et al., 2006) ordinary 
differential equations model for sub-cellular TGF-β1 functions, linked to a 
cellular agent based model of normal human keratinocytes (NHKs) in FLAME 
(www.flame.ac.uk), linked to a multi-cellular layer with a mathematical solver that 
resolved physical issues. 
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• Data: Chemical reactions and coefficient factors of TGF-β1 expression and 
signaling; biological rules for the behavior of normal human keratinocytes (NHK) 
when subjected to injury signals.  
Wound healing research has also been used to investigate inflammatory response at 
the tissue level. The pathogenesis of vocal fold scarring in humans is not well understood 
despite extensive experimental and clinical temporal data from animal studies. Li(N. Y. 
Li et al., 2008) developed an agent-based simulation to model the patient-specific vocal 
fold inflammation and wound healing following acute phonotrauma. 
• Method: Agent Based Model using NetLogo software 
• Data: IL-1β, IL-6, IL-8, TNF-α, matrix metalloproteinase (MMP)-8, and IL-10 
from 4 samples of laryngeal secretions from 9 human subjects.  
Cellular/molecular levels  
Cellular and molecular level approaches offer novel avenues for investigative 
research into disease progression. Computational biology has developed a wide variety of 
methods to model cells, molecular interactions in the form of biological pathways, and 
molecules at varying levels of abstraction(Mary F.  McGuire & Iyengar, 2010 ), along 
with extensive databases of results containing inferred and experimentally validated data. 
The challenge is to how to modify these methods and use these models and data for 
clinical insights into disease progression. 
During the past ten years, signaling pathways have become the cornerstone of cancer 
research(Dy & Adjei, 2008). Signaling pathways are the primary multilevel, multiscale 
communication channels within the organism that regulate physiology(Pawson & Nash, 
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2000; Zhang, Ramesh, Uematsu, Akira, & Reeves, 2008); they clearly play important 
roles in disease progression. Cellular signaling pathways are initiated by extra-cellular 
biological entities including cytokine signaling molecules, hormones and growth factors 
in the blood, lymph or interstitial tissue, and biomechanical stimuli such as tissue 
strain(Knobloch et al., 2008; Lucitti et al., 2007; Morrow et al., 2007). Because signaling 
triggers can be measured noninvasively in biofluids such as serum, urine or saliva, they 
may be useful for monitoring the rapid disease progression found in trauma and critical 
care. Specific patterns of signaling molecules such as cytokines have been associated 
with mortality in septic shock(Waage et al., 1989), critical illness(Roche & Gussler, 
1992), trauma(Roumen et al., 1993), and multiple organ failure(Jastrow et al., 2009). In 
trauma, the signaling molecules activate a pro-inflammatory systemic 
response(Oberholzer, Oberholzer, & Moldawer, 2000) across many pathways to help the 
body fight immediate injury; however, if the “turn off” set of signals is not received in 
time by the pathways in the cells – or a compensatory systemic response is too much or 
too little – death may ensue(Adib-Conquy & Cavaillon, 2009; E. E. Moore et al., 2005).  
Molecular signaling profiles may be one of the keys to personalized medicine; 
however, there is still much work to be done to make them clinically relevant. 
Sachs(Sachs, Itani et al., 2009) created an algorithm to extend acyclic Bayesian network 
theory to permit loops, or cycles, in networks. The resulting Generalized Bayesian 
Network (GBN) is a Bayesian network model of nodes representing molecular data, 
augmented by state nodes and edges representing the statistical dependencies among the 
nodes. As a proof of principle, Sachs used GBN to characterize disease states and patient-
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specific signaling profiles in human follicular lymphoma tumors following B-cell antigen 
receptor stimulation(Sachs, Gentles et al., 2009). The results showed differences in 
comparably diagnosed patients that might influence individual prognosis and therapy. 
• Method: Generalized Bayesian Networks (GBN): Bayesian Networks model of 
the phospho-protein signaling pathway augmented with state nodes for patient and 
disease 
• Data: Flow cytometry measures of six phospho-protein levels (SYK, ERK, p38, 
CBL, SFK, BTK) before and after B-cell antigen receptor signaling. Patient state 
and disease state.  
Another research question is how signaling events trigger cellular responses. 
Signaling pathways that lead to apoptosis are of particular interest in disease progression. 
Using a data-driven computational technique called Model-Breakpoint Analysis, 
Janes(Janes, Reinhardt, & Yaffe, 2008) found that the dynamic range of the molecular 
signals had a greater influence on predicting cytokine-induced apoptotic cellular response 
than either basal or maximally inducible signal strength; results were validated 
experimentally. The results suggest that changes in dynamic range, due to subtle 
molecular amino-acid changes from disease mutations, could lead to pathophysiology.  
• Method: Partial least-squares regression, principal component analysis, equation-
based model breakpoint analysis. 
• Data: Model of cytokine-induced apoptosis based on 7,980 measurements of 
molecular signals that are activated by combinations of the death stimulus, tumor 
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necrosis factor (TNF), together with a survival stimuli of epidermal growth factor 
(EGF) or insulin.  
Petri nets can represent signal transduction networks at varying abstraction levels 
using graphs with molecules for nodes, edges for transitions, and tokens generated by the 
transitions. Petri net models can be constructed from limited knowledge of the pathway 
behavior, with ambiguities resolved through subsequent model validation. Qualitative 
Petri net models can be extended to quantitative stochastic or continuous Petri net models 
by the addition of rate equations(Heiner et al., 2010 ). Simulations of stochastic models 
can be run dynamically, and ordinary differential equation solvers can run static 
deterministic analyses of continuous Petri net models. Heiner(Heiner, Koch, & Will, 
2004) developed and validated a qualitative Petri net model of apoptotic pathways, using 
formal computer science methods to represent pathway structure and behavior. Although 
not directly linked to clinical data, Heiner’s Petri net process model could be perturbed to 
gain insights into apoptosis not easily seen in other representations. 
• Method: Step-wise incremental Petri net modeling with repeated analyses. Linear 
algebra using the incidence matrix and transition vector from the network graph.  
• Data: A published schematic overview of apoptosis, comprising both extrinsic 
and intrinsic pathways, induced by DNA damaging and Fas signals, resulting in 
DNA fragmentation combined with a Fas-induced MAPK (mitogen-activated 
protein kinase) pathway and TNFR-1 receptor-induced pathways. Apoptosis 
inhibitors were not taken into account.  
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Summary  
Research in trauma and critical illness is especially challenging because the effects 
of the original insult can be widespread across the entire body, affecting multiple organ 
systems. Disease progression is typically rapid, measured in hours and sometimes in 
minutes. At present there are growing capabilities to collect vast amounts of temporally 
indexed quantitative and qualitative data at multiple levels, from concentrations of 
biomolecules to sophisticated imaging modalities. These capabilities have the potential to 
support translational “bedside to bench and back” research leading to personalized 
therapies. However, the current resources to integrate and interpret patient-specific data 
within the context of acute illness are still limited and new computational approaches are 
needed(Zenker, Rubin, & Clermont, 2007).  
In this chapter I have presented a selection of computational approaches and data 
sources primarily from systems biology that can be useful for translational clinical 
research in disease progression. Clearly, due to the vast scope and complexity of human 
pathophysiology, no one methodology can be a magic bullet. I believe that judicious 
selection, adaptation, and application of techniques such as these can yield valuable 
insights into the underlying mechanisms of disease progression and help formulate 
effective and personalized therapies. In the next two chapters I present the Pathway 
Semantics Algorithm, a novel computational method that uses matrix algebra to bridge 
biology and medicine for the translational analysis of disease progression.  
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Chapter 3 Pathway Semantics Algorithm: Node Analysis 
Rapid advances in lab technologies have made it easier and cheaper to measure vast 
quantities of molecular data in biofluids and tissue, resulting in exponential growth in the 
amount of quantitative and qualitative data available about molecular pathway 
interactions. In 2001, only 18 pathway websites were active(Wixon, 2001). By 2010, 
more than 205 million molecular interactions were accessible via the Internet(PathGuide, 
2010). There are commercial and publicly available databases of molecular 
interactions(Ingenuity, 2010; Tarcea et al., 2009), biological pathways(Caspi et al., 2008; 
Elliott et al., 2008; Visvanathan et al., 2008; Wixon, 2001), and genomic correlates(L. T. 
Sam et al., 2009).  
Increasingly detailed molecular data from patients can be measured in a timely 
manner. For example, Luminex’s xMAP technology can measure multiplex analysis of 
up to 500 unique analytes in a single test well, generating up to 48,000 data points in less 
than one hour(Luminex, 2010). Recently, the technical ability to efficiently measure vast 
quantities of patients’ molecular data has moved from the bioscience laboratory to the 
patient’s bedside with the advent of lab-on-a-chip sensor technologies(Jokerst & 
McDevitt, 2010; Mark, Haeberle, Roth, von Stetten, & Zengerle, 2010) that can support 
personalized medicine. 
This deluge of molecular data creates opportunities for translational biomedical 
research that connects patients’ disease states and molecular data with existing pathway 
databases. However there is a dearth of algorithms and computationally tractable methods 
that facilitate analysis of bedside-to-bench-and-back information. Researchers have 
47 
called for improved discovery processes(Rifai et al., 2006) and methods for process 
quality assessment(Tuglus & van der Laan, 2008). Plausible and meaningful hypotheses 
must be derived from a deluge of quantitative and qualitative experimental data that are 
spread over a variety of experimental paradigms such as clinical outcome, time, cell cycle 
phase, or molecular localization. In addition to analytical methods, there is a need for 
ways to uncover new findings that lead to interesting hypotheses.    
Studies of scientific discovery have demonstrated that most new findings arise from 
data-driven hypotheses generated from unexpected observations rather than from 
verification of pre-determined hypotheses based on theories(Klahr & Simon, 1999). In a 
bedside-to-bench approach, discovery is driven by patient data collected at the bedside. 
Mechanisms or therapies are confirmed later at the lab bench. Data-driven, evidence-
based molecular patterns are a fundamental component of personalized medicine 
research; the molecular patterns can be used to identify drug targets or candidate 
biomarkers.  
Notable diagnostic successes based on the molecular patterns found in patient data 
include the validation of 14-3-3 proteins found in cerebrospinal fluid (CSF) as diagnostic 
of transmissible spongiform encephalopathies(Hsich, Kenney, Gibbs, Lee, & Harrington, 
1996) and the validation of a panel of 18 urinary molecules that discriminate antibody-
associated vasculitis from other renal diseases(Haubitz et al., 2009). Overall, my goal is 
to advance diagnostic, prognostic and therapeutic knowledge and increase understanding 
of the biological mechanisms underlying disease progression.  
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The challenge of pathway analysis for shock / trauma 
In shock / trauma, cytokine signaling molecules activate a pro-inflammatory 
systemic response(Oberholzer et al., 2000) across many biological pathways to fight 
immediate injury; however, if the compensatory systemic response is too much or too 
little, death or morbidity may ensue(Adib-Conquy & Cavaillon, 2009; E. E. Moore et al., 
2005). Specific cytokines have been associated with mortality in septic shock(Waage et 
al., 1989), critical illness(Roche & Gussler, 1992), and trauma(Roumen et al., 1993). 
Cytokine activity patterns change rapidly within the first 24 hours of trauma, and sets of 
cytokines significantly associated with one outcome at a specific time from insult may 
not be associated with any outcome at another time(Jastrow et al., 2009). 
Today, immunoassay methods provide highly accurate measurements of cytokine 
levels. This measurable cytokine data has great potential for developing therapies that 
minimize the occurrence of possibly preventable syndromes associated with trauma such 
as multiple organ failure. However, it is difficult to draw inferences about the meaning of 
likely molecular patterns without efficient algorithms and techniques. Algorithms that 
select and prioritize molecular patterns for further investigation are beneficial because 
they can limit the exploration space for in vitro and in vivo hypothesis testing, minimize 
risks and costs of experimentation and provide evidence-based information for clinical 
trials research. 
Current approaches to molecular pattern identification in disease include the use of 
high throughput measurement techniques such as mass spectrometry and microarray 
immunoassays and qualitative methods such as text mining and graphical analysis. Mass 
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spectrometry is the most common technique for “unbiased” discovery where all protein 
and peptide components of tissues and biofluids are identified within the capability of the 
equipment. Microarray immunoassays are more sensitive and specific; they measure the 
concentrations of pre-determined analytes using immunological reactions. Both assay 
methods have benefits and drawbacks for clinical usage(Hoofnagle & Wener, 2009). Text 
mining algorithms search published literature for information about molecular function 
and disease associations while graphical analysis uses algorithms from computer science 
to identify subgraph motifs in canonical pathway networks of molecular interactions 
found in diseases. Network-based graphical analysis using gene expression patterns has 
been shown to generate novel hypotheses about the classification of breast cancer 
metastasis, including the finding that some gene associations can only be detected using 
network rather than conventional analysis(Chuang, Lee, Liu, Lee, & Ideker, 2007). 
Systems biology tools model in silico biological pathway systems using computational 
methods that parallel in vitro cell-line and in vivo animal models for hypothesis discovery 
and instantiation(Mary F.  McGuire & Iyengar, 2010). 
There are drawbacks to the current approaches. The most significant molecular 
interactions associated with the disease may appear in a non-canonical pathway(W. X. Li, 
2008) that text mining and in silico modeling may overlook. Although ordinary 
differential equations (ODEs) can provide time-based analysis of biological pathways, 
they usually model a small group of canonical pathways within a single cell and are not 
easily computable at the organism level. For example, an ODE model of one NFκB 
signaling pathway in one cell activated by one TNF-α signaling molecule uses 18 
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nonlinear differential equations, with 33 independent variables and 16 dependent 
variables in a simplified reaction kinetics model(Cho et al., 2003). Hence, additional 
analytical techniques are needed to overcome the research bias towards canonical 
pathway associations.  
In summary, to develop deeper insights into the mechanisms of disease progression 
and to improve treatment, it is useful to examine in detail the biological pathways that are 
activated over time, resulting in differential outcomes. Because patterns of cytokines 
have been shown to change rapidly in trauma, it is likely that their associated biological 
pathways offer clues to the underlying pathophysiology, and perhaps even, what is about 
to happen next. The challenge of pathway analysis for shock / trauma is to develop 
computationally tractable bedside-to-bench methods that can infer the most likely 
biological pathways activated by cytokine signaling, provide an analytical framework to 
examine those pathways in terms of biomedical questions, support inquiries about the 
relationships among the clinical states and the underlying biological progressions, and 
suggest hypotheses as to how treatment might influence physiology to mitigate pathways 
that go out-of-control. 
Using algebra to understand biological pathways in disease progression  
In disease progression, a specific molecular pattern can be associated with a certain 
outcome only within a certain time period(Jastrow et al., 2009). The use of a 
mathematical representation that enables scalable computation can uncover hidden 
molecular patterns associated with disease progression. In particular, representing data in 
matrix form can be a way to perform powerful and tractable computations that analyze 
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and compare changes in molecular patterns over patient outcome, time and other 
stratifications. 
Matrices are extensible and computable in n-dimensions; they provide a theoretically 
sound structure that can be used for biomedical analysis. Matrices can frame biomedical 
questions in a way that can uncover relationships between phenomena and hypotheses 
through algebra. In addition, matrices facilitate analysis over multiple stratifications such 
as time, outcome, and disease states even with constraints such as a small sample size. 
Although the process of converting bio-assay data into matrix representation and using 
matrix algebra to answer questions of biomedical interest is non-trivial, once the 
framework is set up, a multitude of analyses can be performed. 
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In this chapter, I present the Pathway Semantics Algorithm (PSA) that first converts 
the bioassay data to matrix representations and then performs matrix algebra to generate 
clinically useful hypotheses that answer biomedical questions. See Figure 3-1. When 
applied to a trauma research study on time-based cytokine patterns related to multiple 
organ failure (MOF)(Jastrow et al., 2009), PSA revealed novel patterns – beyond those of 
the cytokines – in the evoked biological pathways that differentiated the outcomes of 
MOF or non-MOF. The algorithm differs from use of standalone pathway analyses, such 
as those performed in Ingenuity Pathway Analysis (Ingenuity® Systems, 
www.ingenuity.com), because PSA preprocesses the data before input to Ingenuity 
 
 
 
 
Figure 3-1: Goal of Pathway Semantics Algorithm 
The overarching goal of the Pathway Semantics Algorithm (PSA) is to efficiently 
generate clinically useful hypotheses about disease progression using matrix algebra 
to integrate quantitative and qualitative data. 
Nature
Hypotheses
PSA 
Hypotheses
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Pathway Analysis (IPA), tailoring data to the biological and clinical questions under 
study. 
Herein, the next section outlines the algorithm, followed by a demonstration of PSA 
based on serum cytokine protein data from Jastrow’s prospective observational study at a 
Level I trauma center(Jastrow et al., 2009). The next section presents the results followed 
by a discussion of the matrix algebra approach along with considerations for its 
application. The chapter ends with a summary. 
Algorithm 
PSA first processes the input data to generate biological pathways (Steps 1-2) and 
then maps the results to matrices constructed to answer the biomedical questions under 
study (Steps 3-4). If biological pathways are already available, for example, from 
morphoproteomic tissue analysis(R. E. Brown, 2005), only Steps 3 and 4 need be 
performed. 
Dimensionality Reduction. This process selects characteristic subsets of the 
measured molecules. The assayed molecules are assembled into Significance Sets of 
those molecules that statistically differentiate the disease states over the stratifications 
under study, such as outcome, time period of measurement, cell cycle phase observed, or 
a combination of stratifications. The statistical analysis is utilized as a simple factor 
analysis, or feature extraction tool, to identify significant molecules. 
Pathway Generation. The Significance Set for each stratification group plus the 
statistically observed average values (means or medians as appropriate) for each 
molecule in the group are input to a pathway generation algorithm that expands each set 
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to include its likely neighboring molecules, based on published literature and pathway 
databases. A network diagram is then created of the biological pathways showing the 
interactions among the molecules for each stratification group. 
Convert Network Diagrams to Matrices. Matrix representations, suitable for the 
biomedical questions under study, are created from the network diagrams. The molecules, 
or nodes, in the network diagram are mapped to a node matrix (or vector) of molecules 
over the disease states; the molecular interactions, or edges, in each network diagram are 
converted to a matrix (or vector) of molecular interactions. In the simplest form, the node 
matrix has 1 in a row/column cell if the row molecule (or molecular interaction) is 
present in the column disease state; 0 otherwise. 
Matrix Analysis. Algebra is used to compare the matrices to identify differential 
patterns of molecules and molecular interactions of biomedical significance over 
outcome, time and other stratifications. 
Figure 3-2 illustrates a PSA flow diagram for node analysis as applied to the trauma 
study. 
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Figure 3-2: PSA flow diagram for shock / trauma study node analysis 
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Application 
Trauma is the leading cause of mortality in the US among individuals below 45 years 
of age. In 2006, 156,000 deaths occurred due to trauma; trauma is the cause of 74% of all 
deaths for people ages 15-24(Heron et al., 2008). Multiple organ failure (MOF) – also 
known as Multiple Organ Dysfunction Syndrome – is one of the most potentially 
preventable syndromes arising from trauma, yet its pathophysiology is not well 
understood(Deitch, 1992; Maier et al., 2007). The syndrome is unique in that the organs 
that fail are not necessarily injured from the trauma and that late MOF may arise days to 
weeks after the initial incident. MOF continues to be a leading cause of morbidity in 
patients who survive the initial trauma(Stewart, 2007; Watson et al., 2009). 
As previously reported, non-parametric statistical analysis showed that certain 
cytokine patterns within the first 24 hours from trauma were associated with the outcome 
of multiple organ failure before other symptoms were visible(Jastrow et al., 2009). 
Cytokines are small proteins released by stimulated macrophages, monocytes, T cells, 
and other cells; they bind to specific receptors to induce a wide variety of local and 
systemic responses particularly within the innate and adaptive immune systems(Janeway, 
Travers, Walport, & Shlomchik, 2004). 
PSA used de-identified patient data from the Jastrow study, extracted from the 
UTHSC-H Trauma Research Database with the approval of the Committee for the 
Protection of Human Subjects (Institutional Review Board / IRB) of the UTHSC-H 
(HSC-SHIS-09-0237). The data included serum cytokine measurements, collection times, 
and MOF outcomes for 48 patients from an IRB approved prospective observational 
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trauma study conducted in the Shock / trauma Intensive Care Unit (STICU) at Memorial 
Hermann Hospital, a Level I trauma center in Houston, Texas from January through 
December 2005.  
Laboratory materials and methods 
Twenty-seven cytokines were measured by Bio-Plex immunoassay. See Table 3-1.  
For detailed study methods please see Jastrow(Jastrow et al., 2009). 
Table 3-1: Cytokines in the Bio-Plex Human Cytokine 27-Plex Panel 
 Gene Name UNIPROT ID 
Eotaxin CCL11 P51671 
FGF Basic FGF2 P09038 
G-CSF CSF3 P09919 
GM-CSF CSF2 P04141 
IFN-γ IFNG P01579 
IL-1β IL1B P01584 
IL-1ra IL1RN P18510 
IL-2 IL2 P60568 
IL-4 IL4 P05112 
IL-5 IL5 P05113 
IL-6 IL6  P05231 
IL-7 IL7  P13232 
IL-8 IL8 P10145 
IL-9 IL9 P15248 
IL-10 IL10  P22301 
IL12 (p70) IL12A/B P29459/P29460 
IL-13 IL13 P35225 
IL-15 IL15 P40933 
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IL-17 IL17A Q16552  
IP-10 CXCL10 P02778 
MCP-1  CCL2 P13500 
MIP-1α CCL3 P10147 
MIP-1β CCL4 P13236 
PDGF-BB PDGFB P01127  
RANTES CCL5 P13501 
TNF-α TNF P01375 
VEGF VEGFA P15692 
 
Cytokine measurement was performed according to the manufacturer’s instructions 
using a Bio-Plex multiplexed suspension immunoassay (171-A11127 Bio-Plex Human 
Cytokine 27-Plex Panel, 1 x 96-well, Bio-Rad Laboratories, Hercules, CA). The 
characteristics of the assay varied for each cytokine. According to the manufacturer, the 
assay working ranges had lower limits of 1.4 pg/ml for MIP-1α to 92.6 for IFN-γ, and 
upper limits ranging from 836 pg/ml for MIP-1α to 95,484 pg/mL for TNF-a. Assay 
sensitivity (Limits of Detection, LOD) ranged from 0.6 pg/ml for IL-1β to 6.4 pg/ml for 
IFN-γ. Intra-assay coefficient of variation (%CV) ranged from 5% for IL-10 and IL-15 to 
15% for IFN-γ. Inter-assay %CV ranged from 4% for IL-8 to 11% for IL-6 and 
Eotaxin(Zhou, Ma, Fedynyshyn, Tan, & Wang, 2009). There is no record that the 
manufacturer’s specifications and %CV’s were confirmed during the lab assays.  
Data preparation. To normalize the data to time from injury, measurement times 
were adjusted to the estimated time from trauma insult, including transport time by land 
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or air, as well as hospital time before the start of the resuscitation protocol. If transport 
time was not given, the average time for that mode of transportation (by land or 
helicopter) was used. This was done in order to preserve biological relationships over 
time so that the cytokine pattern activities “lined up” for analysis.  
Of the planned 12,960 measurements, 1,107 were missing; 2,057 were “low” and 74 
“high”, due to readings outside the immunoassay range. Rather than discard the low and 
high measurements, or reduce the actual measurements to ordinal values, the low and 
high readings were converted to numerical values based on the range of each cytokine 
value. High was replaced by 150% of the maximum value of that cytokine; low by 50% 
of the minimum value of that cytokine. This approach was taken because the non-
parametric statistical analysis was itself ordinal - based on rank - to differentiate 
outcomes. For example, [5, 2, 7, low, 9] was replaced by [5, 2, 7, 1, 9]. All five data 
points were retained and the rank order would be the same. Missing data were treated as 
such.  
Because the measured molecules were signaling molecules, the number of molecules 
available to trigger biological pathways was considered more important than their total 
mass. Therefore the cytokine data were converted from pg/ml units to SI units before 
input to the software that generated the most likely biological pathways based on relative 
concentrations of molecules.  
The data were grouped over stratifications to facilitate discrete analysis. This 
preserved the original data without making the continuity assumption that the 
concentrations of the cytokine molecules varied smoothly between measurement times. 
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The cytokine data were partitioned for analysis purposes into 6 groups by time periods: 
hours 2–6, 6–10, 10–14, 14–18, 18–22 and 22–24. The four-hour time period was chosen 
because that was the scheduled time between clinical measurements. 
For clarity and simplicity, the mathematical representation used was limited to 
vectors over time in the form of two-dimensional matrices. 
Step 1: Dimensionality Reduction  
Significance Sets Si=1,I of molecules ci=1,I;a=1,A that statistically differentiated the K 
outcomes qk=1,K over time periods xi=1,I were created based on the non-parametric Mann–
Whitney–Wilcoxon (MWW) test executed in each of 6 time periods within the first 24 
hours from insult. Outcomes were q1 = MOF (multiple organ failure) or q2  = NMOF 
(non-multiple organ failure). Time periods from insult were xi=1,6 = 2–6, 6–10, 10–14, 14–
18, 18–22 and 22–24. The Significance Sets S1, S2 and S6 contained the names of 10 of 
the 27 measured cytokines; S3 and S5 contained 14 cytokines; and S6 had 15 cytokines. 
The names of the cytokines differed in each Si. For example, S1 contained: c1,1= Eotaxin; 
c1,2= G-CSF; c1,3= GM-CSF; c1,4= IFN-γ; c1,5= IL-1ra; c1,6= IL-6; c1,7= IL-8; c1,8= IP-10; 
c1,9= MCP-1 and c1,10= MIP-1β. See Table 3-2. Dimensionality reduction was achieved by 
selecting for further analysis only the group of cytokine molecules identified as 
statistically significant outcome differentiators in each time period – a basic factor 
analysis. 
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Table 3-2: Significance Sets of cytokines over time 
 S1 S2 S3 S4 S5 S6 
Eotaxin X X X X X X 
G-CSF X X X X X X 
GM-CSF X X X X X X 
IFN-γ X  X X X X 
IL-1ra X X X X X X 
IL-5   X X   
IL-6 X X X  X X 
IL-7   X X X  
IL-8 X X X X X X 
IL-9    X   
IL-10  X X X X  
IL-13   X X   
IP-10 X X X X X X 
MCP-1 X X X X X X 
MIP-1β X X X X X  
RANTES     X  
TNF-α    X X X 
Si contains the names of the molecules in the Significance Set in time period xi. X 
represents the median values vi,a,k for each outcome. Note that the significant 
molecules in Si differ by time period, reflecting the dynamic nature of the cytokine 
signaling patterns in shock / trauma progression.  
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For consistency with the original non-parametric statistical analysis, the statistical 
weight vi,a,k was set equal to the median concentrations in pg/ml of each assayed molecule 
ci,a in Si for each outcome qk. Table 2 was expanded to 2 tables, one for MOF and one for 
non-MOF, with the median values for each outcome in place of the “X’s”. 
Step 2: Pathway Generation  
Ingenuity Pathways Analysis (IPA) was used to find the likely neighboring 
molecules because the software provides a literature and pathway database search along 
with a pathway generation algorithm that utilizes weighted lists of molecules (Ingenuity® 
Systems, www.ingenuity.com). The algorithm breaks “ties” about which neighbors to add 
to an evoked network based on the relative weightings of the input molecules(S. 
Ingenuity, 2005). Because the analytes were signaling molecules, the relative numbers of 
molecular signals, rather than the relative weights of the molecules, generate more 
representative biological pathways(M. F. McGuire, Iyengar, & Mercer, 2007). Therefore, 
two additional data modifications were performed. First, the units for the median values 
vi,a,k were converted from concentrations in pg/ml to v´i,a,k, the number of molecules per 
liter (pmol/L) based on the mass of the cytokine in kDa as reported in UniProt 
(www.uniprot.org). Second, certain cytokines must be present in multiples or have 
multiple receptors to send signals. Therefore the v´i,a,k were further adjusted to v´´i,a,k by 
how many molecules were required for one signal. The adjusted calculation details are 
given in the Appendix. 
An IPA data template was prepared for each Si with the assayed molecule weightings 
v´´i,a,k (intensities) for both outcomes qk in time period xi and the molecule’s 
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“Gene/Protein ID”. The molecule was identified by its UniProt Knowledgebase 
(UniProtKB) Accession Number, based on the best match for human (subunit A or chain 
A). Each v´´i,a,k was entered as an “Observation/Expression k”, with k=1 for MOF and 
k=2 for non-MOF. The 6 datasets generated 12 time-stamped network groups with one to 
three 35-molecule networks in each group (the default 35-molecule limit is adjustable.) 
Each group was exported as a text list of molecules (network nodes) and as a graphic 
image of molecular interactions (network edges) The molecules lists were combined to 
identify 193 unique subject molecules. See Figure 3-3.  
 
 
 
Figure 3-3: Biological networks differ by disease state  
Although the same Significance Set of cytokines was used for generation of both 
pathways in a time period, the cytokine median values for each outcome were 
different, resulting in different networks: MOF on the left, non-MOF on the right, at 
hours 10–14 from trauma. (See Appendix for network details not visible at this scale.) 
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Visual inspection shows differences in the biological networks evoked by different 
disease states. Shown in Figure 3-3 are the networks for multiple organ failure (left) and 
non-multiple organ failure (right) based on patient cytokine data at hours 10–14 from 
trauma. Both networks were evoked from the same set of molecules, S3, with different 
median concentrations v´´3,a,k for each outcome qk=1, 2. See the Appendix for all 12 graphs 
that generated the 193 unique subject molecules. 
Step 3: Convert Network Diagrams to Matrices  
A summary list Tr of 193 unique subject molecule names mr was assembled from the 12 
groups and entered into column 1 of two temporal dependency matrices TDMMOF(mr, xi) 
and TDMNMOF(mr, xi), with the headers for columns 2–7 set as the time periods xi and 1 or 
0 in row/column cells z denoting the presence or absence of the molecule as depicted in 
the example matrices in  
Figure 3-4. TDM1 (above), TDM2 (below), show 6 molecules mr over 3 time periods 
xi in 2 outcomes qk. To identify molecular patterns by outcome and over time, a summary 
list mr was compiled of the names of the molecules present in any of the biological 
networks evoked from the assayed molecules. Then a temporal dependency matrix 
(TDM) matrix was constructed for each outcome qk, with the molecule names mr as the 
first column and the time periods xi as the headers across the remaining columns. If the 
molecule was present in the time period in the outcome, a 1 was placed in the 
row/column cell zkri; otherwise 0. The rationale behind this process was to facilitate 
computational comparisons over time and outcome using matrix algebra and logic. 
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Matrix algebra was then used to compare the TDMs over disease state stratifications to 
elucidate disease progression and explore questions of biological significance. 
 
 
 
 
 
 
Figure 3-4: Temporal Dependency Matrices (TDMs) example 
TDM1 (above), TDM2 (below), show 6 molecules mr over 3 time periods xi in 2 
outcomes qk. 
m6  00 0
m5 110
1 01m4
0 1m3 1
m2 1 01
m1 1 10
q1 x1 x2 x3
m6 11 1
m5 001
1 00m4
0 1m3 1
m2 1 01
m1 1 1 0
q2 x1 x2 x3
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Step 4: Matrix Analysis  
The mapping of pathways to matrices enabled a wide variety of computational 
analyses using pathway molecules (nodes) and their interactions (edges) to uncover 
hidden network patterns. Two examples of using node analysis follow. 
Example 1 Node Analysis. Identify molecules mr that appear at least once in both 
outcomes in the same time period xi and at least once in either outcome in a different time 
period. 
Background: Danger-associated molecular patterns (DAMP) in the systemic 
inflammatory response syndrome (SIRS) and sepsis induce the production of pro and 
anti-inflammatory mediators by pattern-recognition receptors (PRR). A dysfunctional 
acute inflammatory response may lead to MOF(Bianchi, 2007; Castellheim, Brekke, 
Espevik, Harboe, & Mollnes, 2009). 
Biomedical questions: In this study, are there molecules that are “time-shifted” in 
different outcomes? Is a molecular interaction continuing past its “normal” innate 
response?  
Hypothesis: If the identified molecules appear in both outcomes at different times, 
then additional research may show how to modulate those molecules to minimize 
negative outcomes. 
Let ZMOF =  
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Let Z´NMOF =  
 
 
 
 
Let Z˝ = ZMOF + Z´NMOF 
 
The cells z˝ri of the resulting matrix Z˝ have a 2 if the molecule mr was present in both 
outcomes in time period xi, a 1 if it was present in one outcome or the other, and 0 if it 
was not present in either. A molecule mr was selected if there was at least one 2 and one 1 
in its row. Using these criteria, four molecules were identified that appeared at least once 
in both outcomes in the same time period and at least once in either outcome in a 
different time period: CIITA, HIRA, IG9, and KSR2. 
Example 2 Node Analysis. Identify molecules that appeared only in one outcome or 
the other in more than one time period. 
Background: Cytokine patterns are associated with different trauma 
outcomes(Jastrow et al., 2009; Maier et al., 2007). 
Biomedical question: Are there molecules in the pathways triggered by the measured 
cytokines that are associated only with one outcome in at least 2 of the 6 time periods 
under study? 
Hypothesis: Molecules that meet these criteria may reveal underlying mechanisms 
that have not yet been associated with specific clinical outcomes. 
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Let MOF_SELECT(mr) = 1,  
 if ; else 0                    (1) 
 
Based on these criteria, four molecules were identified as appearing only in MOF: 
Egfr-Erbb2, IFI6, MRAS and NOD1; no molecules appeared solely in NMOF. 
Results 
The matrix analysis in Step 4 identified eight molecules from the 193 molecules 
evoked by the assayed cytokines whose patterns at different times differentiated 
outcomes. Literature searches were performed on each molecule to ascertain associations 
with multiple organ failure or other shock syndromes. IG9(Calderon et al., 2000) was 
deleted because the molecule’s identification was withdrawn (T. M. Calderon, personal 
communication). See Table 3-3. 
! 
zri >1
i=1,I"( )# $ z ri = 0i=1,I"( )
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Of the seven molecules that differentiated outcomes of MOF or non-MOF, only three 
have been previously been associated with shock / trauma: CIITA, EGFR and NOD1. 
The citations were retrieved from PubMed on February 6, 2010 based on a search for the 
molecule name and the MeSH term “shock,” which includes the following syndrome 
categories: Multiple Organ Failure, Cardiogenic Shock, Hemorrhagic Shock, Surgical 
Shock, Traumatic Shock, and Systemic Inflammatory Response Syndrome (including 
Septic Shock). Following are short descriptions of the seven molecules: CIITA, EGFR, 
HIRA, IFI6, KSR2, MRAS, and NOD1, and what they suggest for shock / trauma 
progression. 
Table 3-3: Molecular patterns of multiple organ failure 
 2–6 6–10 10–14 14–18 18–22 22–24 
CIITA M, N   M M  
EGFR M*  M*    
HIRA N   M, N M  
IFI6    M* M*  
KSR2  M, N M   M 
MRAS M* M*     
NOD1  M*   M*  
 
Key M: appears in MOF, N: appears in non-MOF, M*: appears only in MOF. The 
header row shows the time in hours from trauma. 
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Molecule 1: CIITA 
EntrezGene, UNIPROT ID: EG 4261, P33076 
PubMed search: ("shock"[MeSH Terms] ) AND CIITA[All Fields] 
Known in Shock: Yes(Le Tulzo et al., 2004; Pachot et al., 2005; Pangault et al., 
2006; Wilson et al., 2008) 
Known Functions: CIITA is up-regulated by PPARγ in vascular smooth muscle 
cells, which enhances IFNγ-mediated transcription and rescues the TGFβ 
antagonism(Kong, Fang, Fang, Li, & Xu, 2009). CIITA directly inhibits viral replication 
and spreading; CIITA triggers antigen presentation to CD4+ T cells leading to an 
adaptive immune response(Tosi, Bozzo, & Accolla, 2009). Enteral glutamine decreases 
infectious complications in trauma by protecting the gut. Glutamine administered to the 
post-ischemic gut has been correlated with transcriptional activation of PPARγ. There is 
also smooth muscle in the gut; therefore CIITA may be up-regulated due to the PPARγ 
activated by the administration of enteral glutamine, which has been shown to be safe 
during active shock resuscitation(Santora & Kozar, 2009),(McQuiggan et al., 2008). 
Molecule 2: EGFR 
EntrezGene, UNIPROT ID: EG 1956, P00533 
PubMed search: ("shock"[MeSH Terms]) AND "EGF receptor"[All Fields] 
Known in Shock: Yes(Miettinen et al., 1995; Sanchez, Viladrich, Ramirez, & Soley, 
2007; Viladrich, Sanchez, Soley, & Ramirez, 2008) 
Known Functions: Transactivation of EGFR and ErbB2 protects intestinal epithelial 
cells from TNF-induced apoptosis(Yamaoka et al., 2008). EGF is a potential therapeutic 
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agent for the treatment of sepsis(Clark, Clark, Hotchkiss, Buchman, & Coopersmith, 
2008). 
Molecule 3: HIRA 
EntrezGene, UNIPROT ID: EG 7290, P54198 
PubMed search: ("shock"[MeSH Terms]) AND HIRA[All Fields] 
Known in Shock: No 
Known Functions: HIRA promotes replication-independent nucleosome 
assembly(Eitoku, Sato, Senda, & Horikoshi, 2008). 
Molecule 4: IFI6 
EntrezGene, UNIPROT ID: EG 2537, P09912 
PubMed search: ("shock"[MeSH Terms]) AND IFI6[All Fields] 
Known in Shock: No 
Known Functions: IFI6 is believed to play a critical role in the regulation of 
apoptosis, or programmed cell death and is a marker for interferon beta (IFNB) 
activity(Serrano-Fernandez et al., 2009). 
Molecule 5: KSR2 
EntrezGene, UNIPROT ID: EG 283455, Q6VAB6 
PubMed search: ("shock"[MeSH Terms]) AND KSR2[All Fields] 
Known in Shock: No 
Known Functions: KSR2 regulates insulin sensitivity and glucose(Costanzo-Garvey 
et al., 2009). Hyperglycemia associated with insulin resistance is common in critically ill 
patients(Van Den Berghe et al., 2001). KSR2 inhibits MAP3K8 (Cot, Tpl2) kinase 
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activity and signaling(Channavajhala et al., 2003). Inhibition of MAP3K8 in primary 
human cell types can decrease the production of TNF alpha and other pro-inflammatory 
mediators such as MAP3K3-mediated IL-8 (EG 283455) during inflammatory 
events(Hall et al., 2007). 
Molecule 6: MRAS 
EntrezGene, UNIPROT ID: EG 22808, O14807 
PubMed search: ("shock"[MeSH Terms]) AND MRAS[All Fields] 
Known in Shock: No 
Known Functions: MRAS is involved with adhesion signaling, inducing lymphocyte 
function-associated antigen 1 (LFA-1)-mediated cell aggregation(Yoshikawa et al., 
2007). 
Molecule 7: NOD1 
EntrezGene, UNIPROT ID: EG 10392, Q9Y239 
PubMed search: ("shock"[MeSH Terms]) AND NOD1[All Fields] 
Known in Shock: Yes(Cartwright et al., 2007; Chin et al., 2002; Kim et al., 2008; 
Nembrini et al., 2009). 
Known Functions: Activation of NOD1 has been shown to induce septic shock and 
multiple organ injury(Cartwright et al., 2007). NOD1 protects the intestine from 
inflammation-induced tumorigenesis(Chen, Shaw, Redondo, & Nunez, 2008). NOD1 is 
involved in the direct killing of Helicobacter pylori bacteria in the stomach and 
duodenum by epithelial cells(Grubman et al., 2009). Commensal bacteria promote 
immune homeostasis via the innate immune receptor NOD1(Chen & Nunez, 2009). 
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CIITA, NOD1 and EGFR have been previously associated with shock / trauma. They 
maintain intestinal epithelial cell homeostasis during immune and inflammatory 
responses and appear in MOF pathways in this study. This is consistent with previous 
findings that pathophysiology of the gut (epithelium, mucosal immune system, and the 
commensal bacteria) contributes to critical illness(Clark & Coopersmith, 2007)and to 
multiple organ failure(Hassoun et al., 2001). 
Although four molecules - HIRA, IFI6, KSR2, and MRAS - have not yet been 
associated with shock / trauma, their biological functions seem to be consistent with 
trauma progression. MRAS appears in hours 2–10 solely in MOF; it is implicated in the 
regulation of integrin-mediated leukocyte adhesion in inflammatory and immune 
responses(Yoshikawa et al., 2007). IFI6 appears in hours 14–22 solely in MOF; it 
regulates apoptosis, suggesting that programmed cell death is essential to MOF(Serrano-
Fernandez et al., 2009). HIRA is observed in non-MOF in the first hours, and later in 
MOF. It promotes nucleosome assembly(Eitoku et al., 2008). This may indicate either the 
activation of gene transcription or silencing, with different timings associated with 
different outcomes. Likewise, KSR2 is associated with both outcomes early on, but 
appears solely in MOF in hours 22–24. It regulates insulin sensitivity(Salluh & Bozza, 
2008) and, through inhibition of MAP3K8, decreases pro-inflammatory 
mediators(Channavajhala et al., 2003),(Hall et al., 2007). Hence, the presence of KSR2 
may reflect the up-regulation of pathways in an attempt to modulate the inflammatory 
response after injury. This may be an underlying mechanism related to the fact that 
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insulin resistance and hyperglycemia are common in non-diabetic critically ill 
patients(Van Den Berghe et al., 2001).  
Discussion  
In this application, PSA identified and qualified 7 molecules in patterns across time 
of the progression of multiple organ failure; of these, only 3 had been previously 
associated with any shock / trauma syndrome. A literature search confirmed that the 
molecules’ biological functions were consistent with the current understanding of MOF. 
PSA also highlighted the dynamic nature of trauma response, indicating that molecular 
patterns are specific to certain time periods from insult. PSA uncovered novel molecular 
patterns in shock / trauma using an unbiased data-driven approach that integrated what 
was known about the patient and what was known about molecular interactions. The 
appearance of these patterns made sense within the disease context, and suggested 
hypothetical answers to the biomedical questions about which molecules differentiated 
patient outcomes. All 7 of these molecules were in the evoked biological pathways over 
time and were not measured directly. Instead, they were inferred from published literature 
documenting molecular interactions. 
Although these results provide insights into potential hypotheses that may be useful 
in trauma, the quality of this algorithm depends on quality data from assays, literature and 
biological pathway databases as well as the statistical and network algorithms used. 
Following are some key considerations: 
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Quality of the patient data and the assay method. In the MOF application, 8.5% 
of the data was missing. Only one assay method was used, and, its working ranges and 
limits of detection (LOD) varied depending on the cytokine being assayed. 
Quantity of the patient data. Only 11 of the 48 patients had outcomes of multiple 
organ failure; however, there were several thousand cytokine measurements taken on a 
regular time basis. Because the time periods were based on time from trauma, the number 
of measurements differed in each time period, with the fewest being in the first time 
period 2–6 due to patient travel time and the time of protocol entry. In comparison, this 
sample contained more cytokine data than found in the Trauma Related Database 
(TRDB) of the multi-center, multi-year Inflammation and the Host Response to Injury 
Large Scale Collaborative Program. As of 2008, the TRDB contained only 80 trauma 
subjects with cytokine data sampled irregularly (www.gluegrant.org). 
Dimensionality reduction through Significance Sets. Dimensionality reduction, or 
limiting the number of variables under consideration, was performed to reduce false 
positives, noise and redundancy in the input data and to reduce the computational burden 
in subsequent steps. The trade-off was loss of pattern information. 
Choice of statistical analysis used to identify Significance Sets. In this exploratory 
analysis, I identified six time-based Significance Sets using the Mann–Whitney–
Wilcoxon (MWW) test on two independent samples (MOF or NMOF) over 27 observed 
molecules in each time period. MWW was selected because more sophisticated 
techniques rely on normality, a condition not satisfied in these data sets. In this 
exploratory analysis, I chose to identify six Significance Sets rather than one Significance 
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Set from a repeated measures test in order to yield more a detailed understanding of 
disease progression. With my focus on inclusiveness for hypothesis generation, I 
tolerated the 5% false positive rate in the Significance Sets and the assumption of 
independence of the observed molecules. However, if enough data are available, 
multivariate methods such as MANOVA could be applied to account for correlations 
among the observations. Note that the statistical analysis is being used to judge the 
significance of a variable (e.g. a cytokine in a time period), not the significance of a value 
(e.g. an observation of a patient’s cytokine in a time period.) Given a larger sample size 
with a normal distribution, exploratory factor analysis methods could be used to identify 
the Significance Sets. 
Quality of the biological pathway knowledge base and the algorithm used to 
evoke biological pathways based on assay measurements. PSA used the commercial 
product Ingenuity Pathway Analysis. IPA is well accepted in the biological sciences 
community as seen in several hundred references in PubMed 
(www.ncbi.nlm.nih.gov/pubmed). I chose to use IPA because it is capable of using 
concentration data to generate pathway networks, and has the flexibility to generate 
biological networks of any size incorporating the closest interaction neighbors to the 
input data. To minimize the effects of noise in the data, median values were used as input 
to IPA. The default size of 35 nodes per network was used in this study, with 1 to 3 
networks generated for each outcome in each time period. Each network group was 
combined before matrix analysis, resulting in up to 105 nodes connected by direct and 
indirect molecular interaction edges per time period per outcome. 
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Changing nature of the biological pathway knowledge base. IPA’s knowledge 
base is constantly updated based on current findings. It is likely that somewhat different 
networks will be generated from the same input data each time IPA is run, with the 
newer, more relevant, knowledge base information added to the old. The earlier 
information may have been rescinded or simply only visible in a network larger than 35 
nodes. 
Biological scope of the generated network. If the biological scope is limited to 
certain species or disease states, the generated network will reflect only current 
knowledge with the result that potential molecular interactions in other species and 
disease states may be overlooked. Since the goal of applying PSA to MOF was to 
uncover hypotheses about potential molecular patterns underlying trauma, it was 
preferable to run the IPA network generation algorithm without constraints, with the 
understanding that some of the molecular patterns identified may need to be verified in 
human shock / trauma progression. 
Utility of the molecular patterns. The identified molecules may be difficult to 
assay clinically due to their primary presence in tissue rather than biofluids, low 
concentrations, or lack of existing assays. However, the molecular patterns may be useful 
for in vitro and in vivo verification of the underlying biological mechanisms that may 
elicit more clinically useful information. 
Resource requirements to implement PSA. Published data for time-based analysis 
of biofluids and tissues in disease progression may not be readily available although 
access to biological pathway algorithms and data ranges from free open source to 
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commercial products. This presents opportunities for research studies to collect more data 
in areas such as trauma and critical care where rapid changes are seen and rapid response 
to changing patient condition is required. 
Summary 
This chapter demonstrates that PSA is useful in generating novel hypotheses about 
the significant molecules, or pathway nodes, in the changing biological pathways within 
the first 24 hours of shock / trauma. The PSA matrix algebra approach identified 
differential molecular patterns in biological networks over time and outcome that would 
not be easily found through direct assays, literature or database searches. 
The biological questions of interest in this application of PSA were capable of being 
answered by simple matrix constructions. Insights into more intricate biological 
questions, such as the influence of crosstalk in disease progression, require more complex 
matrix algebra. In the next chapter, PSA is applied to molecular interaction, or “edge”, 
analysis of the evoked pathways in shock / trauma.  
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Chapter 4 Pathway Semantics Algorithm: Edge Analysis 
In recent years, advances in technology have made it possible to measure a wide 
variety of molecules and molecular interactions in cell lines, bio-fluids and tissues. The 
availability of these data has opened new avenues of biomedical research, and challenged 
the scientific community to uncover the meaning of molecular data in contexts ranging 
from cell signaling pathways to phenotype/genotype associations to personalized 
medicine(Weng, Bhalla, & Iyengar, 1999). Molecular interactions offer a rich source of 
information that should be examined in detail to further understand their roles in disease 
progression and outcomes. Computer scientists, mathematicians, physicists, and 
industrial engineers are joining biologists and medical researchers to develop new 
quantitative and qualitative analytical methods to answer questions about underlying 
biological mechanisms and therapeutic efficacies. Algorithms driven by patient data that 
incorporate knowledge bases of molecular patterns are of particular interest because of 
their potential for hypothesis generation in personalized diagnosis, prognosis, and 
therapies. Such algorithms are the focus of my research. 
The Pathway Semantics Algorithm (PSA) described in Chapter 3 generates the most 
likely biological pathways evoked from patients’ molecular data over stratifications such 
as time and/or outcome, and then converts the pathway graphs to matrices of various 
formats depending on the biomedical questions being studied. In the pathway graph and 
the transformed matrix, there are two major types of entities: nodes that correspond to 
specific bio-molecules and edges that correspond to the interactions among the 
molecules. The transformation of graphs to matrices enables the application of powerful 
80 
techniques from matrix algebra to develop mathematical comparison methods, analyses, 
and metrics leading to useful insights into disease progression across time and clinical 
outcomes.  
For example, in the PSA node analysis of Chapter 3, I focused on the molecular 
components of pathway graphs and developed a matrix format called a Temporal 
Dependency Matrix that was instrumental in revealing novel molecular patterns evoked 
from patient data over time in shock / trauma, where disease progression is rapid yet not 
clinically visible. The computational results predicted seven molecules, based on input 
from the original assays, associated with the biological mechanisms underlying multiple 
organ failure; only three had been previously recognized as associated with any shock / 
trauma syndrome. In this chapter I turn my attention to the edges of pathway graphs, 
corresponding to interactions between molecules including genes, RNAs, proteins, or 
chemicals. I applied matrix methods to investigate patterns of molecular interactions 
across time and across clinical outcomes in terms of four functional relationship 
categories: activation, expression, transcription and inhibition. Applying graph theory and 
linear algebra, I found that the interaction patterns of relationship sub-graphs changed 
rapidly within the first 24 hours of trauma insult, and that these patterns differed across 
clinical outcomes of multiple organ failure (MOF) and non-multiple organ failure (non-
MOF). In addition, I developed a numerical metric of crosstalk in molecular pathways 
called XTALK. In contrast to current practice that merely classifies a network in strictly 
binary fashion as having crosstalk or not, XTALK quantifies crosstalk among molecular 
interactions from 0% to 100%, thereby leading to a deeper, fine-grained understanding of 
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crosstalk and its variation due to disease progression. These methods were applied to the 
same shock / trauma data set used in the previous chapter. Results obtained suggest that a 
diagnosis, prognosis or therapy based on molecular interaction mechanisms may be most 
effective within a certain time period and for a certain functional relationship.  
The following sections present background information and definitions relating to 
molecular interactions and mathematical notation, followed by a description of the 
application of the Pathway Semantics Algorithm to analysis of molecular interactions in 
the first 24 hours of trauma progression, the results and a discussion of their meaning, 
concluding with my plans for future work.  
Background 
At a sub-cellular level, molecular interactions can be analyzed using the rules of 
biochemistry when they are represented as sets of differential equations. However, due to 
computational complexity and lack of interaction parameter rate data, this approach is not 
suitable for larger comparative analyses. Instead, molecular interactions, such as protein-
protein or gene-protein interactions, are commonly combined into biological pathway 
networks represented as graphs, where the node, or vertex, is the molecule and the edge is 
the interaction. This representation facilitates the use of qualitative and quantitative 
methods derived from graph theory and algebra because the same biological pathway 
network graph can be mapped to a matrix in different ways, allowing for a choice of 
mathematical methods appropriate to the biomedical question under study.  
Recently, interest has shifted from analysis of nodes, or vertices, in biological 
pathway networks, to examining edges, or links between the nodes(Ahn, Bagrow, & 
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Lehmann, 2010; Evans & Lambiotte, 2009). This parallels the current research into “link 
communities” in social networks, where one person may be connected to several 
overlapping communities of home, work, and interests. In both social and biological 
networks, the edges are directional, showing the influence from one node (a person or 
molecule) upon another in a multi-directional cascade.  
Biological link communities also overlap; a molecule may participate in several 
different interaction categories simultaneously with the same target molecule, or 
inversely, several interactions may occur simultaneously with different molecules to 
achieve the same target function. This latter property has been defined as degeneracy – 
the ability of structurally different elements to perform the same function or yield the 
same output; in contrast, redundancy requires identical elements to perform the same 
function(Edelman & Gally, 2001; Tononi, Sporns, & Edelman, 1999). Degeneracy is a 
key property underlying the robustness of complex adaptive biological systems, such as 
the immune system(Macia & Sole, 2009; Tieri et al., 2010; Whitacre, 2010).  
Crosstalk in biological pathways can be defined as consisting of the redundant 
signaling messages sent over degenerate edges that achieve the same biological function. 
This is consistent with Bruni’s definition that crosstalk exists when edges are functionally 
compatible to, or dependent, on other edges(Bruni, 2007). Crosstalk relates to how 
pathways determine functional specificity, how ubiquitous messengers transmit specific 
information, and how similar messages crosslink within the system while undesired 
signals are minimized. Quantifying crosstalk in patient data-driven biological pathways 
can give insights into the relative robustness of different biological functions and suggest 
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timing and approaches for therapies directed at pathway modulation. For simplicity, this 
study measured crosstalk in one molecular interaction function at a time in each pathway; 
cascades of “mixed-function” molecular interactions that overall would result in 
execution of the same target function were not considered.  
Additional definitions 
Notation and definitions used correspond to those used by Ingenuity Pathways 
Analysis (IPA)(Ingenuity, 2010). The term node is used rather than vertex. 
A molecule is any gene, RNA, protein or chemical. A molecule is represented by a 
node on the directed graph of a biological pathway. 
A relationship is a functional interaction from one molecule to another. A 
relationship is represented by an edge on the directed graph of a biological pathway. A 
directed graph, in mathematical terminology, has specific properties that can be exploited 
computationally. IPA designates relationships as direct or indirect, in a different sense of 
the word “direct”. A direct relationship is a direct physical contact interaction between 
the two molecules. It is represented by a solid line edge. An indirect relationship is an 
interaction that does not require physical contact but is explicitly documented in the 
literature. It is represented by a dotted line edge. A relationship graph is a directed graph 
whose edges are in the same relationship category. Molecules or edges are called 
invariant when they are the same in different stratifications. For example, edges are 
invariant over all time in one outcome if they do not change over all time periods for that 
outcome; alternatively, edges are invariant over outcome if they are the same in both 
outcomes in one time period or more as specified.  
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Let B(E,N) be a directed graph with E edges and N nodes that represents a biological 
pathway with relationship interactions as edges and molecules as nodes. Then A is a 
relationship sub-graph of B with A ⊆ B when ∀ E in A are in the same relationship 
category.  
Pathway Semantics Algorithm for Edges 
Step 1 and Step 2. The Pathway Semantics Algorithm (PSA) first processes the 
input data to generate biological pathways (Steps 1-2) and then maps the results to 
matrices constructed to answer the biomedical questions under study (Steps 3-4). For 
details of Steps 1 and 2 of Pathway Semantics, please see Chapter 3. For this edge 
analysis, relationship sub-graphs were extracted from each pathway for each selected 
molecular interaction relationship within each outcome and time period. The sub-graphs 
were represented as cyclic digraphs (directed graphs with cycles). Each directed edge, or 
arc, of a sub-graph was a one-way interaction relationship from one molecule to another. 
The sub-graphs could also contain loops, or cycles because feedback, feed forward, and 
self-loops occurred in molecular interactions. This necessitated the use of incidence 
matrices for computation and limited graph metrics to those for cyclic digraphs. 
Step 3. Map graphs to matrices.  
In Step 3, the pathway networks were mapped to matrices. Each relationship sub-
graph was mapped to an incidence matrix, called an Edge-Molecule (EM) matrix, where 
each row represented a from-to edge, and each column represented a molecule, with 
doubles for self-loops. A -1 was placed in the from molecule column, a +1 in the to 
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column and 0 otherwise. All molecules evoked in the study were placed in the column 
header row.  
Definition. The incidence matrix M = [mij] of a directed graph B = B(E,N) is a E x N′ 
matrix, M(E,N′) where E = number of edges and N′ = number of nodes (with duplicate 
nodes for self-loops) such that mij = -1 if edge i leaves node j, +1 if edge i enters node j, 0 
otherwise(Bondy & Murty, 2008).  
Step 4. Compare biological pathways using matrices 
In Step 4, algebraic comparisons were performed across stratifications. First, a 
descriptive analysis was performed to count the number of edges in each relationship in 
each outcome over time and to identify edges that were unchanged over time and 
outcome. Linear algebra was then used to calculate XTALK, the crosstalk for each 
relationship, time period, and outcome. With the XTALK measure, relationship sub-
graphs could be analyzed to uncover which functional relationships have the most or the 
least crosstalk in different outcomes and how crosstalk changes over stratifications such 
as time. The XTALK measure is based on the calculation of matrix rank:  
Definition. The rank R of a matrix M is the maximal number of its linearly 
independent columns or rows(Birkhoff & MacLane, 1953). Rank can be calculated using 
Gaussian elimination or singular value decomposition.  
If rank R is greater than or equal to E, the number of edges (rows), then all the edges 
act independently. The percentage, or ratio, of independent edges = R/E, and the ratio of 
dependent edges is 1 - R/E. 
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I propose the biological interpretation that the maximum number of independent 
molecular interactions (edges) required for a molecular function is the same as the rank of 
the incidence matrix constructed from the functional relationship sub-graph, and that a 
measure of crosstalk for that function can be based on the percentage of dependent edges. 
Definition. The XTALK ratio of a directed graph B = B(E,N) with incidence matrix 
M(E,N′) is defined as 1 - (rank (M(E,N′))/E). 
If XTALK = 0%, then all edges act independently for a particular function. The 
XTALK measure includes normalization by the total number of edges in a graph to allow 
comparisons of crosstalk over time and outcome. 
To illustrate the graph mapping to the incidence matrix, see Figure 4-1 and Table 
4-1, representing a network with 3 edges and 3 nodes. The calculated rank of the 
incidence matrix for the graph is 2. This means that 2 edges are independent and 1 edge is 
dependent. It can be seen that the path along the edge_A_C is a combination of 
edge_A_B followed by edge_B_C. The network shows the property of degeneracy: the 
target function can be achieved by edgeA_C or by the edgeA_B followed by the 
edgeB_C. With rank R = 2, and the number of edges = 3, XTALK = 1-(2/3) = 33%, 
suggesting there exists one-third crosstalk in the biological functional relationship 
represented by the graph.  
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On completion of Step 4, the results were reviewed in the light of published 
literature and expert opinion to generate targeted hypotheses about the molecular 
mechanisms of disease progression that may be verified clinically or in the lab.  
Application 
As mentioned in Chapter 3, trauma is the cause of 74% of all deaths for people ages 
15-24(Heron et al., 2008). Disease progression in shock trauma is rapid and deadly; 
patients who survive the initial trauma may suffer morbidity from potentially preventable 
syndromes such as multiple organ failure (MOF)(Stewart, 2007; Watson et al., 2009). 
The pathophysiology underlying MOF is still unclear(Deitch, 1992; Maier et al., 2007). 
Patterns of signaling molecules called cytokines(Janeway et al., 2004) have been 
associated with patient outcomes in trauma and critical care for some time(Hranjec et al., 
2010; Jastrow et al., 2009; Roumen et al., 1995; Visser, Pillay, Koenderman, & Leenen, 
2008; Vodovotz, 2010) and analysis of the biological pathways evoked from cytokines 
may offer insights into disease progression.  
 
Figure 4-1: Graph example 
A
B
C
Table 4-1: Incidence matrix for Figure 4-1 
 A B C 
edge_A_B -1 1 0 
edge_B_C 0 -1 1 
edge_A_C -1 0 1 
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De-identified patient data from the Jastrow study(Jastrow et al., 2009) were extracted 
from the UTHSC-H Trauma Research Database with the approval of the Committee for 
the Protection of Human Subjects (Institutional Review Board / IRB) of the UTHSC-H 
(HSC-SHIS-09-0237). The data included serum cytokine measurements, collection times, 
and MOF outcomes for 48 patients from an IRB approved prospective observational 
trauma study conducted in the shock / trauma Intensive Care Unit (STICU) at Memorial 
Hermann Hospital, a Level I trauma center in Houston, Texas from January through 
December 2005. Twenty-seven cytokines were measured by the Bio-Plex Human 
Cytokine 27-Plex Panel.  
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Although all 27 cytokines were used in the previous PSA molecule (node) study, 
only 11 were used in this edge analysis due to export limitations of the pathway 
generation software (Ingenuity Pathway Analysis) and the fact that all edges had to be 
manually transcribed. The 11 cytokines were chosen by the shock trauma clinicians as 
those most likely related to multiple organ failure. See Table 4-2. In addition, the analysis 
was limited to three time periods: hours 6–10, 10–14, and 22–24 hours from trauma; two 
outcomes: multiple organ failure (MOF) and non-multiple organ failure (non-MOF); and 
Table 4-2: Eleven cytokines were used for PSA edge analysis 
  Gene Name UNIPROT ID 
Eotaxin CCL11 P51671 
G-CSF CSF3 P09919 
GM-CSF CSF2 P04141 
IFN-γ IFNG P01579 
IL-1β IL1B P01584 
IL-1ra IL1RN P18510 
IL-2 IL2 P60568 
IL-6 IL6  P05231 
IL-8 IL8 P10145 
IL-10 IL10  P22301 
TNF-α TNF P01375 
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four relationship categories of molecular interactions: activation, expression (including 
metabolism and synthesis for chemicals), inhibition and transcription, for a total of 24 
pathway network graphs. The relationships are defined by Ingenuity Systems (Ingenuity 
Systems, personal communication) as follows:  
• Activation: includes activation events such as activation, activity, stimulation, 
reactivation, and specific activity.  
• Inhibition: includes inhibition events such as inhibition, desensitization, 
inactivation, repression and autoinhibition.  
• Expression: includes expression events such as expression, upregulation, 
downregulation, translation, production, microRNA targeting, and induction.  
• Transcription: includes transcription events such as including transcription, 
germline transcription, transactivation, and transrepression   
Both direct and indirect interactions were used in the edge analysis. Direct 
interactions required that two molecules make direct physical contact with each other and 
included chemical modifications, such as phosphorylations, if there was evidence that the 
two factors involved interacted directly rather than through an intermediary. Although 
indirect interactions did not require physical contact between the two molecules, the 
interactions had to be explicitly stated in the literature – not inferred(Ingenuity, 2010). 
The edge analysis was performed for each relationship, time, and outcome using the EM 
matrices, generating edge counts and crosstalk as defined in Section 3. The IPA pathway 
network graphs for this analysis were generated from September to November 2008.  
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Results 
Steps 1 and 2 of PSA evoked 24 IPA network graphs of the most likely biological 
pathways. Note that multiple graphs for an outcome in a time period were consolidated 
into a single graph. A total of 1,264 edges were examined among the 132 molecules 
evoked in the first 24 hours from insult; each edge was identified by its outcome, time 
period, “FROM” molecule, “TO” molecule, and molecular interaction relationship 
category. See Figure 4-2 for one graph; all are shown in the Appendix. 
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Figure 4-2: Evoked biological pathways in MOF at hours 6–10  
The “expression” interaction edges are highlighted in gray. White nodes are the 
evoked “nearest neighbor” molecules; shaded nodes are the input molecules in the 
Significance Set. The darker the shade, the higher the measured median value. 
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EM Matrices 
In Step 3, the edges were mapped into twenty-four EM matrices by outcome, time 
period, and category. Duplicate molecule columns were added to the 132 molecule 
columns in all EM matrices to include the 12 molecules that had self-loop interaction 
edges. This was required to enable the from-to edge. The 12 molecules with self-loop 
feedback were: CCL11, CCNA1, Cyclin A, Cyclin E, IL6, TNF, IFNG, IL1, IL10, 
Hsp70, RARB, and MYBL2. The final number of columns in each EM matrix was 144, 
with the number of row edges changing according to the interaction type and the time 
period. Figure 4-3 shows a portion of the EM matrix for the Figure 4-2 graph. 
 
 
 
 
 
Figure 4-3: Section of EM matrix for network shown in Figure 4-2 
 
IL6
CSF3 
IL8 IL1
CSF2
IL10 
MOF 6_10 expression
FROM_TO CSF2 CSF3 IL1 IL6 IL8 IL10
CSF3_IL8 0 -1 0 0 1 0
CSF3_IL6 0 -1 0 1 0 0
CSF3_IL10 0 -1 0 0 0 1
IL1_CSF3 0 1 -1 0 0 0
CSF2_CSF3 -1 1 0 0 0 0
94 
 
 
Edge Counts 
Dominant functions. Based on the Step 4 edge count, the most interactions per time 
period were in the activation function category, except in hours 22–24 for non-MOF 
when activation interactions were fewer than expression interactions. Inhibition and 
transcription interactions were most active in hours 10–14. See Figure 4-4. 
 
 
Invariant interactions across all time. No inhibition interactions were consistently 
present during the three time periods. Two transcription interactions were present in both 
MOF and non-MOF: PDGF BB, which is involved in the transcription of CSF2 (GM-
 
 
 
Figure 4-4: Edge interactions over time, outcome, and functional relationship 
Results show the most activity in hours 10–14 from trauma.  
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CSF) and IL1 (IL-1β), which increases transcription of IL8. PDGF BB is a platelet-
derived growth factor homodimer that causes mitosis in cells of mesenchymal origin; 
here it affects the transcription of CSF2, which encodes a cytokine that controls the 
production, differentiation, and function of granulocytes and macrophages. IL1 is a 
cytokine produced by activated macrophages that mediates the inflammatory response, in 
this case by increasing transcription of IL8, a chemokine that functions as a neutrophil 
polymorphonuclear cell (PMN) chemoattractant. It is also a potent angiogenic factor. 
Unique interactions in each time period. Although the majority of molecular 
interactions were similar in each time period over both outcomes, distinct differences 
were revealed by a count of the edges unique to MOF or non-MOF. See Figure 4-5. In 
hours 6 to 10 from trauma, there were twice as many unique activation interactions in 
non-MOF than MOF; whereas by hours 10–14, MOF surpassed non-MOF with a greater 
number of unique interactions in all categories. In hours 22–24, MOF had twice as many 
unique activation edges than non-MOF, although both had the same number of unique 
expression edges. There were few unique inhibition or transcription interactions. Overall, 
there were more interactions that appeared solely in MOF than in non-MOF. Another 
point of interest is that IL6 was involved in ~50% of the unique expression interactions in 
both outcomes in the first 6–10 hours, while IFNG became dominant in hours 10–14.  
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Crosstalk 
XTALK, a measure of crosstalk based on the dependency between the functional 
edges as calculated by matrix rank, ranged from 0% to a high of 71%, and changed over 
time. See Figure 4-6. 
Activation. Activation crosstalk was calculated at ~69% in hours 6–10, staying 
steady to 71% at hours 10–14, and decreasing in hours 22–24 to 45% in MOF and 32% in 
non-MOF. 
 
Figure 4-5: Unique edge interaction counts 
These edges are in addition to the invariant interactions in each time period that are in 
both outcomes. 
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Expression. In hours 6–10, expression edge crosstalk was 51% in MOF and 46% in 
non-MOF. This increased in hours 10–14 with MOF rising to 62% and non-MOF to 54%. 
Crosstalk then decreased in hours 22–24 to 27% in MOF and 31% in non-MOF.  
Inhibition. There was no crosstalk in inhibition interactions in hours 6–10 and 22–
24; however, crosstalk increased to 17% in MOF and 20% in non-MOF in hours 10–14. 
Transcription. 9% transcription crosstalk was calculated in both outcomes in hours 
6–10, rising to ~21% in hours 10–14, then decreasing to 0% by hours 22–24.  
 
 
 
 
 
Figure 4-6: Crosstalk in functional relationships across time and outcome 
Percentages calculated using the XTALK measure. 
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Interaction Summary 
Activation. In hours 6–10, there were twice as many unique activation edges in non-
MOF compared to MOF; however the reverse was the case in the later time periods. This 
may imply that in non-MOF, a large number of favorable molecular interactions were 
underway early, so fewer unique activations were needed as the pathways approached a 
favorable outcome of non-MOF. The percentage of activation crosstalk was about the 
same in hours 6–10 and 10–14 in both outcomes, decreasing only in hours 22–24.  
Expression. By hours 10–14, MOF had more than three times the number of unique 
expression edges than non-MOF, implying higher energy consumption in MOF 
metabolism than in non-MOF at this time. The percentage of expression crosstalk was 
slightly lower in non-MOF than MOF in the first two time periods, changing to slightly 
higher by the end. 
Inhibition. Unique inhibition interactions appeared solely in MOF in the last two 
time periods. Crosstalk appeared in both outcomes only during hours 10–14; it was 
slightly higher in non-MOF. Again, this suggests an attempt to damp down molecular 
interactions in both outcomes starting in hours 10–14 that was continued in hours 22–24 
by additional unique inhibitory interactions in MOF. 
Transcription. Unique transcription interactions appeared in both outcomes in hours 
10–14, with the majority in MOF. Crosstalk in transcription interactions increased 
initially, and disappeared in both outcomes by hours 22–24 when only two transcription 
interactions occurred in each outcome. 
99 
Discussion 
Today it is generally accepted that there is a need to develop computational, data-
driven algorithms to exploit the vast quantity of molecular information available in 
knowledge bases in order to advance systems biology and to improve patient 
care(Aristotelis, 2006; Wenyuan Li, Xu, & Zhou, 2010 ; Ruths, Nakhleh, Iyengar, Reddy, 
& Ram, 2006; Tipney et al., 2009; Veliz-Cuba, Jarrah, & Laubenbacher, 2010). Due to 
several successes(Kanehisa, Goto, Furumichi, Tanabe, & Hirakawa, 2009; Sachs, Gentles 
et al., 2009; L. Sam, Liu, Li, Friedman, & Lussier, 2007), in silico hypotheses generators 
are no longer denigrated as “fishing expeditions”(Brent & Lok, 2005).  
The Pathway Semantics Algorithm (PSA) is an initial in silico data integration and 
analysis step towards formulating hypotheses about disease progression for personalized 
diagnosis, prognosis, and therapies that can be validated in the laboratory and in the 
clinic. PSA is based on a novel, flexible approach that uses graph theory and numerical 
algebra to computationally compare non-canonical biological pathways evoked from 
patient data over time.  
PSA was applied to a prospective observational study of shock / trauma, a research 
area where patient data is sparse and difficult to obtain even at a Level I trauma center; 
randomized controlled trials are not an option. By using patients’ molecular cytokine data 
to evoke non-canonical biological pathways from the Ingenuity Pathway Knowledge 
Base, PSA expanded the existing information to include the most likely molecules and 
molecular interactions evoked by the patients’ cytokines. With the expanded information 
set, and its representation as pathway graphs, PSA was able to use computational tools 
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and algorithms from graph theory and numerical algebra to compare patterns of 
molecules and molecular interactions over different stratifications. In particular, PSA was 
able to analyze patterns over time – an absolute necessity for clinicians who treat disease 
as it unfolds(Shahar, 2000). This feature shows the potential of PSA to support temporal 
reasoning in medical decision-making and support systems. 
Overall response to trauma insult 
The results from these analyses suggest that molecular interaction activity – and the 
nature of that activity – changed dramatically within the first 24 hours of trauma. In both 
outcomes, the number of interactions peaked during hours 10–14 from insult, lessening to 
about half of the initial activity by hours 22–24; this may be due to the effects of 
interventions during the first 24 hours combined with the innate systemic response. There 
were core sets of molecular interactions that were invariant over outcomes in each time 
period plus unique interactions only in one outcome or the other. This suggests a primary 
molecular response to the injury that was modulated by the unique interactions edges 
towards favorable or unfavorable outcomes. MOF had fewer unique interactions early in 
response, but by hours 10–14, MOF had almost three times as many unique edges as non-
MOF – perhaps an excessive number.  
Changes in the gene regulation process 
Multiple organ failure has been characterized as an adaptive, multilevel time-based 
stress response with marked changes in gene expression(Adib-Conquy & Cavaillon, 
2009; Cobb, Buchman, Karl, & Hotchkiss, 2000; Warren et al., 2009). I believe that this 
is the first study to quantify the changing aspects of gene expression in MOF over time. 
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By examining edge interactions in silico, changes in functional relationships and their 
crosstalk over time and outcome were revealed. 
Molecules must be activated before they can be transcribed and then expressed, and 
inhibition can halt any step in the gene regulation process. It is known that cells respond 
quickly to stress by altering their metabolism; they can induce apoptosis or cell-cycle 
arrest and alter nuclear pathways for DNA repair(Boulon, Westman, Hutten, Boisvert, & 
Lamond, 2010). Activation interactions dominated the initial response in both outcomes 
through hours 10–14, showing the immediate cellular response to stress. Expression was 
higher in MOF, suggesting a higher metabolic load on the system. Inhibition and 
transcription interactions were a small proportion of the overall count.  
Crosstalk changes over time and outcome 
For demonstration purposes, I performed a simple analysis that did not include 
interaction cascades of different functions in order to focus on a “black box” of four 
dominant functions. Even with this limitation, differences were observed across time and 
outcome. This is important because it suggests that a diagnosis, prognosis or therapy 
based on molecular data might only be valid within a certain time period and for a certain 
functional relationship, due to the degeneracy in the biological network. For example, 
because there appear to be few inhibition relationships and little or no inhibition crosstalk 
in initial trauma, it may be worth exploring increasing inhibition interactions early on in 
order to limit the excessive unique expression interactions in MOF in hours 10–14. 
Crosstalk decreased over time in the first 24 hours from trauma, suggesting that therapies 
should consider time from insult as well as which interaction functions they are targeting 
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in order to be effective. This also suggests that trauma therapies may have to be 
administered in a particular sequence, similar to certain cancer therapies.  
Study considerations and limitations 
The quality of the PSA results depends on the quality of the patient data, the clinical 
study protocol, the assay method, the choice of statistical analysis, and the accuracy of 
the biological pathway networks generated by the Ingenuity Pathway Algorithm from its 
knowledge base. Some key considerations for this edge analysis are as follows: 
Age of pathway data. IPA generated the biological networks evoked in this study in 
Fall, 2008. Since that time, there have been extensive, continuous updates to the IPA 
knowledge base. It is not possible to access older versions of the knowledge base 
(Ingenuity Systems, personal communication) nor is it possible to export interaction data 
in other than graphical formats, resulting in extensive manual transcription before 
computation can be done. Therefore, this chapter is intended as a demonstration of the 
algorithm, and the actual biomedical results may differ somewhat based on current 
research. My assumption is that the evoked biological networks will primarily be the 
same, with the difference that new discoveries may bring new “closest neighbors” into 
the graph, pushing out existing molecules past the default 35 node limit per graph. This 
can be addressed by generating new graphs with larger node limits. In addition, the 
relationships between molecules may be augmented with new relationships or reclassified 
to related relationships. However, as with published research, older information about 
relationships is rarely deleted. 
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Incomplete pathway data. Some functional relationships may be more highly 
represented in the Ingenuity Pathways Knowledge Base than others due to the type of 
experiments performed in the published research, rather than the reality of the true 
proportion of those relationships in nature. This was addressed in the crosstalk 
calculation by normalizing XTALK by the number of edges in each relationship sub-
graph to facilitate comparison across stratifications. 
Linearity assumption. Using matrix rank as a basis for the XTALK measure 
implies that the edges are related in a linear manner – that is, each edge can be 
represented as a combination of nodes with coefficients of -1, 0, or 1. This can be 
considered to be a linear approximation to a non-linear function, computed by taking the 
first term in the representative Taylor series.  
Conclusions and Future Work  
The Pathway Semantics Algorithm identified different patterns of molecular 
interactions over time, outcomes, and functional relationships in biological networks that 
would not be easily found through direct assays, literature or database searches. The 
differences in the number of edges, the number of unique edges, and the XTALK ratios 
show the utility of evaluating a molecular interaction not just as a connection between 
two molecules, but as a directed interaction from one molecule to another that may carry 
out one or many specific functions(Wu, Zhang, Yu, & Ouyang, 2009). The crosstalk 
measure XTALK provided a novel perspective on the changing functional interaction 
relationships in disease progression; the results supported the existence of the property of 
degeneracy in biological networks.  
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Chapter 5 Experimental Results / Findings 
Introduction 
The Pathway Semantics Algorithm was validated by experimental findings in the 
disease domain of hemophilia A in an ongoing study of the cellular immune response to 
factor VIII (FVIII), an essential blood-clotting factor. The study is being conducted by 
Keri Csencsits Smith, PhD, Assistant Professor, Department of Pathology and Laboratory 
Medicine at the University of Texas Medical School at Houston.  
Background 
Hemophilia A is a disease characterized by a deficiency in FVIII clotting activity 
that results in bleeding episodes. The disease is managed by intravenous infusions of 
FVIII after the onset of bleeding, and, in severe cases, by prophylactic infusions of FVIII 
concentrate several times during a week to prevent spontaneous bleeding(Brower & 
Thompson, 1993). However, as many as one-third of hemophilia A patients develop 
inhibitor antibodies to FVIII, and these patients can no longer receive infusion 
therapy(Zakarija et al., 2011). Alternative therapies to manage hemophilia A patients 
with FVIII inhibitors are expensive and not often successful.  
Several causes, including genetics and inflammatory response, have been proposed 
that may influence the production of inhibitor antibodies. Dr. Csencsits Smith’s project 
focuses on cytokine signaling. Because specific cytokines mediate T cell help for B cell 
antibody production(Bray et al., 1993), modifying cytokine response may prevent or 
reduce inhibitor formation. Recently, T cells that secrete IL-17 (known as TH17 cells) 
have been linked with the development of inflammatory disease(Korn, Bettelli, Oukka, & 
105 
Kuchroo, 2009). A compound called colonization factor antigen I (CFA/I), derived from 
human enterotoxigenic Escherichia coli, has been shown to decrease TH17 response and 
increase the number of T cells that can regulate the immune response(Jun et al., 2005; 
Kochetkova, Trunkle, Callis, & Pascual, 2008; Ochoa-Reparaz et al., 2008).   
The Pathway Semantics Algorithm (PSA) was used to assess how CFA/I treatment 
modified the immune response in a mouse model by examination of the pathway 
networks evoked from cytokine profiles over time. The hypothesis was that CFA/I would 
reduce the formation of inhibitor antibodies by decreasing TH17 response. PSA was then 
validated in the laboratory by confirmation of the presence of a predicted molecule from 
mouse splenocyte culture supernatant. 
Materials and Methods 
Laboratory. FVIII-deficient mice (B6;129S4-F8tm1Kaz/J; Jackson Laboratories)(Bi 
et al., 1995) were intravenously immunized with 2 µg recombinant human FVIII 
(Kogenate®; Bayer) weekly for 4 weeks.  This protocol resulted in the production of 
anti-FVIII antibodies with inhibitory capacity(Qian, Borovok, Bi, Kazazian, & Hoyer, 
1999; Reipert, Ahmad, Turecek, & Schwarz, 2000). Production of inhibitor antibodies 
was confirmed by Bethesda assay. Beginning 3 days before the initial FVIII 
immunization, mice received either 100 µg of colonization factor antigen I (CFA/I) 
isolated from human enterotoxigenic Escherichia coli (E. coli) fimbriae or control sterile 
phosphate-buffered saline (PBS) via intranasal instillation. Mice were euthanized on days 
7, 14 and 28 post-primary FVIII injection, and splenocytes were isolated and cultured for 
72 hours in PRMI-1640 media + 10% fetal bovine serim (FBS).  Tissue culture 
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supernatants were harvested and used as directed in a MILLIPLEX™ Mouse 
Cytokine/Chemokine 22-plex Panel 
(www.millipore.com/catalogue/item/mpxmcyto70kpmx22) and results analyzed by 
Luminex 100. 22 cytokines were measured in pg/ml for each treatment for each day, 
resulting in 6 cytokine profiles.   
All procedures incorporated in the studies were reviewed and approved by the 
University of Texas Medical School. The investigation was guided by the Veterinarian 
Director of the Animal Resource Facility and associates with regard to handling, 
analgesics and euthanasia for these studies. The Animal Resource Facility is fully 
accredited by the American Association for the Accreditation of Laboratory Animal Care 
for the use of warm-blooded animals in research, training or other activities sponsored by 
grants, awards or contracts. 
In silico. The Pathway Semantics Algorithm used the mouse (Mus musculus) 
cytokine data for a node analysis of the biological pathways evoked by the treatments of 
PBS or CFA/I at two time points: day 7 and day 14. There was insufficient data for day 
28 at the time of the PSA analysis. Each mouse cytokine was identified by its gene name. 
Its UNIPROT Accession ID was used to obtain the molecular weight, which was adjusted 
by the number of receptors required for signal transduction. See Table 5-1. Method 
details for node analysis have been previously detailed in Chapter 2. 
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Table 5-1: Cytokines measured in Hemophilia A study 
 Gene 
Name 
UNIPROT 
Accession 
ID 
UNIPROT 
MW of the 
unprocessed 
precursor 
# 
receptors 
reqd for 
signal 
Weighted 
value for 
signal 
transduction 
divide 
pg/ml 
by__ to 
get 
pmol/L 
G-CSF Csf3 P09920 22,421 1.0 22421 22.4 
GM-CSF Csf2 P01587 16,091 1.0 16091 16.1 
IFN-γ Ifng P01580 17,907 2.0 35814 35.8 
IL-1a Il1a P01582 31,023 1.0 31023 31.0 
IL-1b Il1b P10749 30,931 1.0 30931 30.9 
IL-2 Il2 P04351 19,400 1.0 19400 19.4 
IL-4 Il4 P07750 15,834 1.0 15834 15.8 
IL-5 Il5 P04401 15,410 2.0 30820 30.8 
IL-6 Il6 P08505 24,384 1.0 24384 24.4 
IL-7 Il7 P10168 17,727 1.0 17727 17.7 
IL-9 Il9 P15247 16,075 1.0 16075 16.1 
IL-10 Il10 P18893 20,673 2.0 41346 41.3 
IL-12 p35 Il12a P43431 24,179 2.0 48358 48.4 
IL-13 Il13 P20109 14,108 1.0 14108 14.1 
IL-15 Il15 P48346 18,593 1.0 18593 18.6 
IL-17 Ctla8 Q62386 17,490 2.0 34980 35.0 
IP-10 Cxcl10 P17515 10,789 1.0 10789 10.8 
KC Cxcl1 P12850 10,254 1.0 10254 10.3 
MCP-1  Ccl2 P10148 16,326 1.0 16326 16.3 
MCP-1a Ccl3 P10855 10,345 1.0 10345 10.3 
RANTES Ccl5 P30882 10,071 1.0 10071 10.1 
TNF-α Tnf P06804 25,896 3.0 77688 77.7 
22 mouse (Mus musculus) cytokines were measured in pg/ml. For pathway generation, 
the median values of the Significance Sets were converted from pg/ml to a signal-
transduction weighted pmol/L, which more accurately represented the signal strength. 
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Step 1. Dimensionality Reduction. Statistical analysis was performed using the non-
parametric Mann–Whitney–Wilcoxon (MWW) test (www.spss.com) to identify the 
Significance Sets of molecules that differentiated the treatments on both days.  
Step 2. Ingenuity Pathways Analysis (IPA) was used to find the likely neighboring 
pathways molecules (Ingenuity® Systems, www.ingenuity.com). Although the inputs 
were identified as mouse cytokines, the pathway generation algorithm was not limited by 
species in order to include information from other species’ pathways that may not have 
yet been discovered in mouse pathways. 
Step 3. The IPA network diagrams were converted to temporal dependency matrices 
(TDMs), one for each day and each treatment.  
Step 4. The TDMs were compared to identify molecules that differentiated the 
treatment of PBS or CFA/I. 
Laboratory. Based on the PSA results, an immunoassay test would be performed on 
mouse supernatant for at least one of the predicted molecules at one time point to validate 
the PSA. The molecule(s) tested would depend on availability of the appropriate 
laboratory kit(s) to Dr. Csencsits Smith.  
Results 
PSA identified the Significance Sets of measured cytokines that statistically differentiated 
treatment of PBS (control) or CFA/I (p<.05, Mann Whitney) on day 7 as IL-5, RANTES 
(CCL5), and TNF-α; on day 14 as G-CSF, IL-1a, IL-12, IL-13, IP-10 (CXCL10). The 
median pmol/L values of the significant cytokines were entered into IPA for both 
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treatments on both days to generate the most likely biological pathways. Four network 
graphs were generated as shown in Figure 5-1, Figure 5-2, Figure 5-3, and Figure 5-4. 
 
Figure 5-1: PBS Day 7 
 
 
 
PBS is the “control” group. The molecules used for pathway generation are shaded: 
IL-5, RANTES (CCL5), and TNF-α (TNF). 
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Figure 5-2: CFA/I Day 7 
 
 
CFA/I is the treatment by a novel tolerogenic protein. Both networks were generated 
based on the same Significance Set of 3 molecules; however, very different networks 
resulted due to the difference in the median values between treatments. In PBS, IL-5 
had the lowest concentration whereas in CFA/I, TNF-α had the lowest concentration. 
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Figure 5-3: PBS Day 14 
 
 
 
The molecules used for pathway generation on day 14 were G-CSF, IL-1a, IL-12, IL-
13, IP-10 (CXCL10).  
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Figure 5-4: CFA/I Day 14 
 
There was little difference in the evoked networks for day 14 although both networks 
were generated based on a larger Significance Set of 5 molecules than in day 7.  
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Lists of the evoked molecules were assembled and counted; there were a total of 79 
molecules. See Table 5-2. 
 
 
The unique day 7 molecules are shown in Figure 5-5. Day 14 evoked LGAL59 and 
PKCa/b for PBS and CCL6 & LBP under CFA/I treatment. Of particular interest on day 7 
is the fact that PBS evokes defensin and TLR-2/TLR-4 and pro-inflammatory cytokines 
of the IL-1 family. CFA/I evokes GT1b ganglioside that may decrease expression of 
certain T-cell antigens; HLX, a transcription factor which may regulate the TH1 pathway, 
and pro-inflammatory cytokines of the TNF family plus IL-25 (IL-17E), a cytokine 
favoring the TH2-type immune response. By day 14, even though there were more 
cytokines in the Significance Set than on day 7, the evoked networks only differed by two 
molecules each, suggesting that the effects of the CFA/I treatment were time limited. 
Table 5-2: Evoked pathway molecule count 
 Day 7 & 14 Day 7 Day 14 
PBS only 0 16 2 
CFA/I only 0 16 2 
PBS & CFA/I 9 10 24 
 
79 molecules were evoked in the generated pathways for both outcomes on both days. 
Of these, 36 appeared solely in one treatment.  
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 Because of the study hypothesis that T cells that secrete IL-17 have been linked with 
the development of inflammatory disease, and the fact that IL-25 (IL-17E) – a cytokine 
that favors a response opposite to that of IL-17 (IL-17A-F) – was evoked in the CFA/I 
treatment on day 7, a validation test was run to compare the presence of IL-25 in the day 
7 PBS and CFA/I supernatants.  
Laboratory Method and Results. The immunoassay used was the R&D Systems 
Mouse IL-17E (IL-25) Duoset ELISA kit (www.rndsystems.com/pdf/DY1399.pdf). Mouse 
spleens were harvested at the indicated time, and lymphocytes isolated by mechanical 
dissociation followed by water lysis to remove red blood cells. CD4+ T cells were 
enriched using an EasySep Mouse CD4+ T cell enrichment kit 
(www.stemcell.com/en/Products/Popular-Product-Lines/EasySep.aspx), and 1 x10^6 T 
Figure 5-5: Unique evoked pathway molecules on Day 7 
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cells/ml were cultured for 72 hours in RPMI-1640 media (ATCC) supplemented with 
10% fetal calf serum (FCS, Atlanta Biologicals) in the presence of 3 U/ml recombinant 
IL-2 (R&D Systems), 10 microg/ml FVIII (Kogenate FS, Bayer Pharmaceuticals), and 5 
x 10^5/ml mitomycin c -treated feeder cells. Supernatants were harvested and stored at -
80 degrees C before use in the ELISA. 
Test results showed that the concentration of IL-25 was almost twice as high in the 
CFA/I treatment as in the control PBS treatment. See Figure 5-6. This suggests that the 
CFA/I treatment alters the immune signaling networks involved in the production and 
prevention of anti-FVIII antibodies in a mouse model of hemophilia A.  
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Discussion 
The Pathway Semantics Algorithm used cytokine data from a mouse model of the 
disease hemophilia A to generate hypotheses about the progressive changes in the 
immune response in anti-factor VIII antibody production. The experimental finding of the 
predicted IL-25 molecule in the CFA/I treated group supports the study hypothesis that 
CFA/I modulates the TH17 response. Although IL-25 (IL-17E) has significant sequence 
homology to the IL-17 family(Lee et al., 2001), the molecule has very different 
properties. The laboratory result that IL-25 decreased in both the PBS control and the 
Figure 5-6: Validation of predicted IL-25 at day 7 
 
 
 
Using an ELISA immunoassay test for IL-25, the hypothesized predominance of IL-
25 in CFA/I was confirmed. Supernatant from cultures of splenocytes isolated from 
untreated mice had 615 pg/ml of IL-25, similar to PBS on day 28. 
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CFA/I treatment to a level close to cell culture controls by day 28 is consistent with the in 
silico prediction that by day 14 CFA/I treatment effects would diminish. This is of 
interest because, although there were more measured molecules that statistically 
differentiated the treatments on day 14 than day 7, the evoked biological pathways on day 
14 were almost identical. Based on this result, Dr. Csencsits Smith is planning 
experiments on the timing for repeated CFA/I treatments to manage inhibitor production 
because the peak response seemed to be at 7 days based on PSA. 
Although these results are promising, there is much work to be done. In addition to 
the considerations given in Chapter 2 about the Pathway Semantics Algorithm and its 
reliance on external data, more laboratory validation is required. The presence of the one 
predicted molecule that supports the study hypothesis is a beginning. What PSA brings is 
the ability to use multi-cytokine panels of measured data to infer non-measured 
molecules and interactions. For the Laboratory Scientist, the Pathway Semantics 
Algorithm narrows the scope for exploration, thus reducing labor and costs associated 
with lab research and potentially increasing the chance for novel discovery.  
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Chapter 6 Conclusions and Suggestions for Future Research 
Conclusions 
Problem Statement. There is a need to connect bioassay data with pathway 
information within specific biomedical contexts and to facilitate comparison of biological 
pathways by time, outcome, and other stratifications. If these needs could be met, clinical 
research could start utilizing the wealth of constantly updated pathway information on a 
regular basis to generate baseline hypotheses for biological mechanisms, diagnosis, 
prognosis and therapy.  
Problem Assessment. Based on an extensive literature survey of computational 
methods, there appears to be no generalizible, computable systems-level methods that 
utilized spatiotemporal bioassay data to answer biomedical questions arising from 
comparative analysis of biological pathways.  
Research Goal. To address this need, the overarching aim of my dissertation project 
was to develop a computationally tractable and mathematically sound algorithm that 
enabled hypotheses generation about mechanisms of disease progression based on 
quantitative and qualitative data from molecular and clinical sources.  
Research Deliverable. I developed a novel method called the Pathway Semantics 
Algorithm (PSA) that used matrix algebra to bridge the gap between biological and 
clinical resources by improving the in silico identification of clinically useful hypotheses 
about molecular patterns in disease progression. By framing biomedical questions within 
a variety of matrix representations, PSA has the flexibility to analyze combined 
quantitative and qualitative data over a wide range of stratifications. The resulting 
119 
hypothetical answers can then move to in vitro and in vivo verification, research assay 
optimization, clinical validation, and commercialization.  
Application Findings. PSA identified differential temporal patterns of molecules 
and molecular interactions in pathways evoked from measured cytokines in two disease 
domains: shock / trauma and hemophilia A. The PSA results were validated by literature 
and expert opinion, and also by experiment for hemophilia A. In the node analysis 
described in Chapter 3, PSA identified and qualified 7 molecules in patterns across time 
of the progression of multiple organ failure; of these, only 3 had been previously 
associated with any shock / trauma syndrome. In the edge analysis described in Chapter 
4, PSA identified different patterns of molecular interactions over time, outcomes, and 
functional relationships in biological networks evoked during the progression of multiple 
organ failure. Differences in the number of edges and unique edges for each stratification 
were uncovered, showing the changing temporal patterns of the molecular functions of 
activation, expression, inhibition, and transcription during the first 24 hours of trauma. In 
addition, the novel matrix-based measure XTALK gave quantitative insights into 
functional crosstalk in disease progression; the calculated results supported the existence 
of the property of degeneracy in biological networks. 
Algorithm Generalizations. PSA confirmed that computationally tractable matrix 
algebra can integrate disparate quantitative and qualitative data for analysis over many 
stratifications, even where data is sparse, such as in shock / trauma studies. In addition, 
matrix algebra can facilitate computational time-based analysis that is usually thought of 
as requiring differential equations or complex time series. By discretizing the data into 
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time periods related to clinical measurement intervals, molecular data analysis can be 
synchronized with the ongoing clinical care.  
Application Generalizations. The Pathway Semantics Algorithm has been designed 
as a general method that can be applicable to a wide range of translational biomedical 
research. For example, stratifications over time, outcome, and interaction function were 
demonstrated; others could be used, such as cell cycle or sub-cellular molecular location 
if the data is available. The data requirements depend on the pathway generation software 
used; for IPA, a wide variety of data types are supported. 
Algorithm Limitations. The Pathway Semantics Algorithm is built from validated 
quantitative components such as statistics and algebra, and the pathways come from 
qualitative peer-reviewed biomedical literature through the Ingenuity Knowledge Base. 
An extensive review of the literature, including the material in Chapter 2, showed that 
there are no standard methods for connecting bioassay data with pathway information 
within specific biomedical contexts or for comparing biological pathways over time and 
other stratifications. In addition, there seem to be no standard approaches for assessment 
of such methods and no established procedure to validate hypotheses derived from 
pathway models. It can be argued is that the gold standard is verification of hypotheses in 
vivo. Such an extended study is clearly beyond the scope of this research project. Instead, 
an informal content validity assessment of PSA by literature and expert opinion has been 
performed during a four-year period, during which time it has not been discredited; 
summary details follow in the validation section. Recently, PSA was confirmed 
experimentally in the hemophilia A study. Due to the network export limitations of the 
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IPA software and the resulting extensive manual labor currently involved, PSA has yet to 
be formally documented for estimates of reliability and validity(Higgins & Straub, 2006); 
it is planned to do this once PSA is automated and application results updated.  
Application Limitations. Although these results provide insights into potential 
hypotheses that may be useful in disease progression, the quality of the PSA algorithm 
depends on quality data from assays, literature and biological pathway databases as well 
as the statistical and network algorithms used. Due to the small sample sizes in the 
disease domains under study, it was not feasible to perform a cross-validation of the 
results. In cross-validation, the input data is partitioned into training and test sets. The 
results would be analyzed to see if different hypotheses arise(Gutierrez-Osuna, 2009; W. 
Li, Arena, Sussman, & Mazumdar, 2003). In addition, the Pathway Semantics Algorithm 
was not formally assessed for reliability through a test-retest procedure(Nunnally, 1978) 
due to lack of automation; it is planned to do this in future applications. 
  The limitations of the PSA node analysis were detailed in chapters 3 and 4. 
Summarizing, the results rely on: 
• Quality of the patient data and the assay method 
• Quantity of the patient data 
• Dimensionality reduction through Significance Sets 
• Choice of statistical analysis used to identify Significance Sets 
• Quality of the biological pathway knowledge base and the algorithm used to 
evoke biological pathways based on assay measurements 
• Changing nature of the biological pathway knowledge base 
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• Biological scope of the generated network 
• Utility of the molecular patterns 
• Resource requirements to implement PSA 
Additional limitations resulted from the edge analysis described in Chapter 4: 
• Age of pathway data 
• Incomplete pathway data 
• Linearity assumption 
Validation of Algorithm and Application Results. The Pathway Semantics 
Algorithm was first presented for public critique in 2007. Since then, PSA, its 
applications and results have been informally reviewed and validated for content by 
multi-domain experts at conferences in systems and computational biology, trauma and 
critical care, operations research, pathology and numerical algebra. Presentations have 
been as follows; two awards have been received: 
Signaling Pathways in Multiple Organ Failure (Poster).  
• The Eighth International Conference on Systems Biology. October 1–6, 2007. 
• Research Day, University of Texas Health Science Center at Houston. October 
19, 2007. 
• Rice University 2007 Computational Biology Symposium. December 8, 2007. 
Temporal Analysis of Signaling Pathways in Multiple Organ Failure (Presentation). 
• 7th International Conference on Complexity in Acute Illness/International Shock 
Conference, Cologne, Germany, July 2008. 
123 
• 7th International Conference on Pathways, Networks, and Systems Medicine; 
Corfu, Greece. Aegean Conferences 2009.  
• NLM Informatics Training Conference 2009: Portland, OR June 2009. 
Measurement Units May Impact Results of Pathway Analysis (Abstract) 
• Journal of Critical Care. 2007 International Conference on Complexity in Acute 
Illness (ICCAI)]. 2007;22(4):342-3.  
Measuring Crosstalk in Biological Pathways (Poster) 
• 2009 Keck Center Annual Research Conference, Houston, TX, October 2009. 
• Research Day, University of Texas Health Science Center at Houston. November 
20, 2009. (Poster Award: 2nd Place Student Clinical and Translational Research) 
• Annual Meeting of the Association of Clinical Scientists, San Antonio, TX May 
2010 (Presentation). 
• NLM Informatics Training Conference 2010: Denver, CO June 2010. 
• Conference on Numerical Linear Algebra: Perturbation, Performance, and 
Portability: Austin, TX July 19–20, 2010. 
• The Ninth International Conference on Complexity in Acute Illness. Atlanta, GA 
September 10–12, 2010.  
• INFORMS Annual Meeting 2010: Austin, TX, Nov 7–10, 2010. (Finalist Student 
Competition). 
Uncovering Immune Signaling Networks Involved in Anti-FVIII Antibody Production 
in a Mouse Model of Hemophilia A Via Computational Analysis. (Poster)  
• 2010 Keck Center Annual Research Conference, Houston, TX, October 2010. 
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Implications and Expected Contributions to Science. The use of matrix 
representation and numerical algebra, as used in the Pathway Semantics Algorithm 
(PSA), offers a way to computationally integrate and analyze qualitative and quantitative 
approaches for improved hypothesis generation about disease progression. PSA identifies 
and compares likely temporal molecular patterns in biological pathways derived from 
patients’ data, an important benefit that supports personalized medicine and that may 
reduce the costs of disease research by narrowing the scope towards more likely 
hypotheses.  
This dissertation research project advances science in two areas: informatics and 
translational biomedicine. Informatics is advanced by the demonstration that Pathway 
Semantics facilitates the integration of qualitative and quantitative data, and along with 
statistical and mathematical processing, strengthens the information content upon which 
hypotheses are generated. The methodology appears to be repeatable, generalizable, 
scalable and extendable. Translational biomedicine is advanced because Pathway 
Semantics is designed to overcome the knowledge barrier between the ability to measure 
abundant quantitative molecular data and the ability to connect that data with qualitative 
biological pathway mechanisms that evoke hypotheses of clinical and biological 
significance. 
Suggestions for Future Research 
Algorithm. Additional software development is required to automate the Pathway 
Semantics Algorithm for node and edge analysis in general. As a composite method, PSA 
now relies on commercial software processing components for statistical analysis, 
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algebraic calculations, and biological network generation. The first two are generally 
available as open source links; however, network generation algorithms and pathway data 
are usually proprietary. Current intellectual property restrictions by Ingenuity Systems 
have required extensive workarounds to utilize the data in the Ingenuity Knowledge Base 
in a manner acceptable under the license provisions and also useful for PSA; it is 
expected that meetings with Ingenuity Systems will continue on how to resolve this. 
Meanwhile, other sources of biological pathway data and network generators are under 
review. Once PSA is automated, future enhancements include support of data 
perturbation analysis combined with support for probabilistic scenarios. In perturbation, 
or sensitivity, analysis, the input data is changed incrementally and the stability of the 
output hypotheses is assessed(Geard, Willadsen, & Wiles, 2005). For probabilistic 
scenarios, the generated hypotheses can be strengthened by Bayesian inference, a form of 
inductive reasoning commonly used in medical decision-making to assess the value of a 
diagnostic test(Sox, Blatt, Higgins, & Marton, 1988). As an example, instead of using 
median cytokine values to generate representative signaling pathways, a researcher could 
use 75% values and see how the evoked pathways change. Combined with a sensitivity 
analysis of biological pathways evoked from bioassay data, PSA could then be used for 
“rule-in”/”rule-out” guidelines for clinical interpretation of molecular signaling data.  
Application. I plan to continue analysis of disease progression in shock /trauma with 
re-runs of all cytokine data collected in the original study. This will update the generated 
biological pathways with the latest research, and add additional patient data 
measurements beyond the first 24 hours already studied. The hypothesis is that biological 
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pathways evoked in the first 24 hours from trauma differ from those in later times due to 
changes in systemic response. The hemophilia A study continues, with the intent of using 
patients’ cytokine data as they become available.  
In a very different way, I plan to apply PSA to analysis of cancer progression within 
the context of molecular tumor profiling. In chronic conditions such as cancer, the time 
course is slower and the focus is on the molecules within the signaling pathways in 
tumors that may be targeted by drugs. Instead of time, the component molecules in the 
signaling pathways need to be evaluated by their cellular location, such as cytoplasm or 
nucleus, and their cell cycle phase to determine cellular dysfunctions. Measurements 
from molecular tumor profiling (using MorphoproteomicSM analysis by 
immunohistochemistry(Tan, 2008)) include expression of signaling molecules in 
compartment locations and analytes relating to cell cycle phase. This approach is used for 
patients with tumors that have no established protocol or that have not responded to 
conventional therapy(Robert E. Brown, Lun, Prichard, Blasick, & Zhang, 2004). Here 
there is a need for an analysis of signaling pathways in tumor profiles that compares 
molecular expression across specific locations and cell cycle phase for a better 
understanding of the pathways that differentiate cancers. This will assist in the choice of 
therapy for hard-to-manage cases. 
Summary 
The fundamental contribution of this research project is the methodology called the 
Pathway Semantics Algorithm (PSA) as one solution towards the goals of connecting 
bioassay data with pathway information within specific biomedical contexts and 
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facilitating comparison of biological pathways by time, outcome, and other stratifications 
to further diagnosis, prognosis and treatment for disease progression. This is a novel 
approach to meet the need for both hypothesis and data driven strategies for result 
analysis and interpretation of clinically derived data(Ghazal, 2008); this work advances 
both informatics and translational biomedicine.  
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Chapter 3 
Adjusted weightings for IPA: pg/ml to pmol/L  
Note: calculations are only for the 17 cytokines in the Significance Sets Si 
 Gene 
Name 
UNIPROT 
Accession 
ID 
UNIPROT 
MW of the 
unprocessed 
precursor 
# 
receptors 
reqd for 
signal 
Weighted 
value for 
signal 
transduc-
tion 
divide 
pg/ml 
by__ to 
get 
pmol/L 
Eotaxin CCL11 P51671 10732 1.0 10732 10.7 
G-CSF CSF3 P09919 22293 2.0 44586 44.6 
GM-CSF CSF2 P04141 16295 1.0 16295 16.3 
IFN-γ IFNG P01579 19348 0.5 9674 9.7 
IL-1ra IL1RN P18510 20055 1.0 20055 20.1 
IL-5 IL5 P05113 15238 1.0 15238 15.2 
IL-6 IL6  P05231 23718 1.0 23718 23.7 
IL-7 IL7  P13232 20187 1.0 20187 20.2 
IL-8 IL8 P10145 11098 1.0 11098 11.1 
IL-9 IL9 P15248 15909 1.0 15909 15.9 
IL-10 IL10  P22301 20517 1.0 20517 20.5 
IL-13 IL13 P35225 14319 1.0 14319 14.3 
IP-10 CXCL10 P02778 10881 1.0 10881 10.9 
MCP-1  CCL2 P13500 11025 1.0 11025 11.0 
MIP-1β CCL4 P13236 10212 1.0 10212 10.2 
RANTES CCL5 P13501 9990 1.0 9990 10.0 
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Biological Networks generated from IPA in September 2009 (based on 27 cytokines) 
Graphic images were exported on January 17, 2010. Measured input molecules in 
pink to red; the darker the color, the higher the concentration. Solid lines are direct 
interactions; dotted lines, indirect interactions. Here line color has no meaning; it resulted 
from merging several networks.  
 
TNF-α TNF P01375 25644 3.0 76932 76.9 
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     3-1 MOF hours 2-6 
   3-2 NMOF hours 2-6 
 
 
IL12 (complex)
CCL2
Jnk
IL1
NFkB (complex)
CSF2VitaminD3-VDR-RXR
Interferon alpha
IFN Beta
CCL11
HLA-DR
Hsp70
Ap1
IL6
LDL
STAT5a/b
Fibrinogen
SAA@
IL8
Nfat (family)
Ifn gamma
CXCL10
Tgf betaIL1RN
CCL4
CSF3
Tlr
NfkB-RelA
P38 MAPK
IKK (complex)
Vegf
C1q
MHC Class II
IFNG
IgG
Egfr-Erbb2
G
MRAS
Mapk
TNFSF11
BDNF
VEGFC
ERK
Rap1
Histone h4
ERK1/2
EGF
SELE
MAP2K2
Pdgf Ab
HDAC9 (includes EG:9734)
PDGFB
Akt
PDGF-AA
RNA polymerase II
Histone h3
FAK
NEU3
CRP
PI3K
PDGF BB
IL1R1
CXCL11
MAP2K1/2
TLR2/TLR4
Ras
CIITA
INS
Networks 1,2 Merged 4
 © 2000-2010 Ingenuity Systems, Inc. All rights reserved.
 
IL12 (complex)
CCL2
Jnk
IL1
NFkB (complex)
CSF2
VitaminD3-VDR-RXR
Interferon alpha
IFN Beta
CCL11
HLA-DR
Hsp70
Ap1
IL6
LDL
STAT5a/b
Fibrinogen
SAA@
IL8
Nfat (family)
Ifn gamma
CXCL10
Tgf beta
IL1RN
CCL4 CSF3
Tlr
NfkB-RelA
P38 MAPK
IKK (complex)
Vegf
C1q
MHC Class II
IFNG
IgG
G
Mapk
IG9
TNFSF11
BDNF
VEGFC
ERK
NTN1
Rap1
Histone h4
ERK1/2
HIRA
C5AR1
SELE
IER2
RHOB
HDAC9 (includes EG:9734)
PDGFB
Akt
RNA polymerase II
Histone h3
FAK
NF1
Rap1-gp91-p22 phox-p40 phox-p47 phox-p67 phox
CRP
MUC4
PI3K
PDGF BB
CXCL11
MAP2K1/2
Ras
EGF
CIITA
INS
Networks 1,2 Merged 5
 © 2000-2010 Ingenuity Systems, Inc. All rights reserved.
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 3-3 MOF hours 6-10 
  3-4 NMOF hours 6-10 
 
Tlr
CXCL10
IL1
LDL
NFkB (complex)
Jnk
CCL2
ERK1/2
IL1RN
MHC Class II
Ifn gamma
IL8
CCL11
PDGF BB
P38 MAPKFibrinogen
IL10
IL12 (complex)
SAA@
IgG
Mmp
STAT5a/bAp1
CSF3
IL6
IKK (complex)
Vegf
Interferon alpha
PI3K
HLA-DR
CSF2
CCL4
NfkB-RelA
MAP2K1/2
IFN Beta
PDGF-AA
CEACAM6 (includes EG:4680)
ERK
TFF3
ST14
CNR2
Akt
MRAS
1,2-dipalmitoylphosphatidylcholine
SELE
P2RY6
NOD1
SCARB1
TFF2
GHRL
IL8RB
FAK
G-protein gamma
Mapk
cyclic GMP
PDGFB
Il8r
PROS1
Rap1
INS
KSR2
LAT2
Ras
Nfat (family)
NEU3
RNA polymerase II
CRP
G
Networks 1,2 Merged 6
 © 2000-2010 Ingenuity Systems, Inc. All rights reserved.
 
Tlr
CXCL10
IL1
LDL
NFkB (complex)
Jnk
CCL2
ERK1/2
IL1RN
MHC Class II
Ifn gamma
IL8
CCL11
PDGF BB
P38 MAPK
Fibrinogen IL10
IL12 (complex)
SAA@
IgG
Mmp
STAT5a/b
Ap1 CSF3
IL6
IKK (complex)
Vegf
Interferon alpha
PI3K
HLA-DR
CSF2
CCL4
NfkB-RelA
MAP2K1/2
IFN Beta
IL17R
CEACAM6 (includes EG:4680)
ERK
TFF3
CNR2
Akt
RIPK2
1,2-dipalmitoylphosphatidylcholine
SELE
P2RY6
SCARB1
TFF2
PDGF-AA
GHRL
FAK
Mapk
cyclic GMP
PDGFB
Il8r
BDNF
Rap1
INS
KSR2
LAT2
Ras
Nfat (family)
NEU3
RNA polymerase II
CRP
PGF
leukotriene D4
G
Networks 1,2 Merged 7
 © 2000-2010 Ingenuity Systems, Inc. All rights reserved.
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    3-5 MOF hours 10-14 
  3-6 NMOF hours 10-14 
 
 
Tlr
CXCL10
IL1
NFkB (complex)
LDL
CCL2
Il12 receptor
Cyclooxygenase
IL1RN
Fibrinogen
MHC Class II
Ifn gamma
C1q
CCL11
IL13
Igm
IL7
IL10
IL12 (complex)
SAA@
Nos
Ige
IL-2R
CSF3
Arginase
P38 MAPK
HLA-DR
Iga
CSF2
CCL4
IgG
NfkB-RelA
Interferon alpha
IFN Beta
IL5
Mmp
Vegf
MAP2K1/2
Jnk
ERK
VitaminD3-VDR-RXR
JAK
PI3K
Cpla2
Hsp70
Ap1
TFF2
IL6
STAT5a/b
Mek
Akt
ERK1/2
Mapk
PDGF BB
Pka
Histone h3
Histone h4
Rap1
Tgf beta
Egfr-Erbb2
IL8
KSR2
IKK (complex)
FAK
DUOX1
Ras
Nfat (family)
RNA polymerase II
IFNG
G
Networks 1,2 Merged 8
 © 2000-2010 Ingenuity Systems, Inc. All rights reserved.
 
Tlr
CXCL10
IL1
NFkB (complex)
LDL
CCL2
Il12 receptor
Cyclooxygenase
IL1RN
Fibrinogen
MHC Class II
Ifn gamma
C1q
CCL11
IL13
Igm
IL7
IL10
IL12 (complex)
SAA@
Nos
Ige
IL-2R
CSF3
Arginase
P38 MAPK
HLA-DR
Iga
CSF2
CCL4
IgG
NfkB-RelA
Interferon alpha
IFN Beta IL5
IG9
Vegf
MAP2K1/2
Jnk
ERK
VitaminD3-VDR-RXR
JAK
PI3K Cpla2
Hsp70
Ap1
Mmp
STAT5a/b
Mek
Akt
ERK1/2
Mapk
PDGF BB
Pka
Histone h3
Histone h4
IL1F9
Tgf beta
IL8
Rap1
IKK (complex)
FAK
Ras
AIF1
Nfat (family)
RNA polymerase II
KIR2DS2
IFNG
G
IL6
Networks 1,2 Merged 9
 © 2000-2010 Ingenuity Systems, Inc. All rights reserved.
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 3-7 MOF hours 14-18 
  3-8 NMOF hours 14-18 
 
 
Tlr
CXCL10
Ikb
IL1
IL10
Tnf receptor
Il12 receptor
Cyclooxygenase
IL1RN
Ifn gamma
C1q
CCL11
IL13
Fcgr3
Igm
IL7
MHC CLASS I (family)
IL12 (complex)
CCL4
Nos
STAT5a/b
IL-2R
CSF3
HLA-DR
Arginase
SAA@
IKK (complex)
Hat
IL5
TNF
CSF2
IgG
NfkB-RelA
CCL2
IL9
Mmp
TCR
MAP2K1/2
Jnk
Ige
NFkB (complex)
ERK
Interferon alpha
IFN Beta
Cpla2
Hsp70
Ap1
LDL
Mek
Iga
Akt
ERK1/2
Mapk
PI3K
Il8r
Tgf beta
PLA2
STAT
Hdac
IL8
Rap1
Rac
P38 MAPK
Vegf
Ras
Nfat (family)
MHC Class II
PDGF BB
IFNG
hCG
Calpain
lipoxin A4
DDR2
G
TMOD1
IFI6
PPARGC1B
RARB
ESR1
GPR56
NCOA1
CDKN1A
HIRA
TCF7L2 (includes EG:6934)
Pka
IL32
Histone h4
VitaminD3-VDR-RXR
NfkB1-RelA
RNA polymerase II
Histone h3
FAK
Collagen(s)
CREBBP
LZTS1
IFI27
MT1F
KLF6
CYP24A1
CIITA
GC-GCR dimer
HOXA10
Networks 1,2,3 Merged 10
 © 2000-2010 Ingenuity Systems, Inc. All rights reserved.
 
Tlr
CXCL10
Ikb
IL1
IL10
Tnf receptor
Il12 receptor
Cyclooxygenase
IL1RN
Ifn gamma
C1q
CCL11
IL13
Fcgr3
Igm
IL7
MHC CLASS I (family)
IL12 (complex)
CCL4
Nos
STAT5a/b IL-2R
CSF3
HLA-DR
Arginase
SAA@
IKK (complex)
Hat
IL5
TNF
CSF2
IgG
NfkB-RelA
CCL2
IL9
Mmp
TCR
MAP2K1/2
Jnk
Ige
NFkB (complex)
ERK Interferon alpha
IFN Beta
Cpla2
Hsp70
Ap1
LDL
Mek
Iga
Akt
ERK1/2
Mapk
PI3K
Il8r
Tgf beta
PLA2
STAT
Hdac
IL8
Rap1
Rac
P38 MAPK
Vegf
Ras
Nfat (family)
MHC Class II
PDGF BB
IFNGhCG
Calpain
GPR56
HOXA10
LGALS3BP
G
TMOD1
PPARGC1B
CAPN3
ESR1
NCOA1
CDKN1A
HIRA
Pka
IL32
Histone h4
HLA-G
PTMA
MMP11
Talin
VitaminD3-VDR-RXR
Histone h3
FAK
MT1F
Collagen(s)
CAMK4
CREBBP
POLR2F
LZTS1
IFI27
ADCY5
DDR2
CYP24A1
RNA polymerase II
TRIM21
Networks 1,2,3 Merged 11
 © 2000-2010 Ingenuity Systems, Inc. All rights reserved.
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    3-9 MOF hours 18-22 
  3-10 NMOF hours 18-22 
 
 
Tlr
CXCL10
Ikb
IL1
Tnf receptor
Il12 receptor
Cyclooxygenase
IL1RN
Fibrinogen
MHC Class II
Ifn gamma
C1q
CCL11
MHC CLASS I (family)
Fcgr3
TimpIL7
IL10
IL12 (complex)
CCL4
Nos
STAT5a/b
IL-2R
CSF3
HLA-DR
SAA@
IKK (complex)
Hat
TNF
CSF2
IgG
NfkB-RelA
Interferon alpha
IFN Beta
CCL2
CCL5
Mmp
TCR
Pld
CD3
Jnk
NFkB (complex)
ERK
JAK
Cpla2
Ap1
IL6
LDL
FAK
Mek
Iga
Akt
ERK1/2
Mapk
MAP2K1/2
PDGF BB
P38 MAPK
PI3K
Il8r
Tgf beta
PLA2
STAT
IL8
Rap1
Rac
Hsp27
Vegf
Ras
Nfat (family)
hCG
Calpain
PTGER4
IFI6
G
CTSS
MT1F
G-protein beta
Cyclin E
Hsp90
Hdac
Histone h4
HIRA
C5AR1
HDAC9 (includes EG:9734)
Pka
IFNG
DNAJB7
GPR56
NOD1
VitaminD3-VDR-RXR
RNA polymerase II
Histone h3
Collagen(s)
ST13
CCR3
IGFBP7
KIR2DS2
Cyclin A
IL1F9
DDR2
Hsp70
CIITA
IFI27
Networks 1,2,3 Merged 12
 © 2000-2010 Ingenuity Systems, Inc. All rights reserved.
 
Tlr
CXCL10
Ikb
IL1
Tnf receptor
Il12 receptor
Cyclooxygenase
IL1RN
Fibrinogen
MHC Class II Ifn gamma
C1q
CCL11
MHC CLASS I (family)
Fcgr3
Timp
IL7
IL10
IL12 (complex)
CCL4
Nos
STAT5a/b
IL-2R
CSF3
HLA-DR
SAA@
IKK (complex)
Hat
TNF
CSF2
IgG
NfkB-RelA
Interferon alpha
IFN Beta
CCL2
CCL5
Mmp
TCR
Pld
CD3Jnk
NFkB (complex)
ERK
JAK
Cpla2
Ap1
IL6
LDL
FAK
Mek
Iga
Akt
ERK1/2
Mapk
MAP2K1/2
PDGF BB
P38 MAPK
PI3K
Il8r
Tgf beta
PLA2
STAT
IL8
Rap1
Rac
Hsp27
Vegf
Ras
Nfat (family)
hCG
Collagen(s)
IGFBP7
VitaminD3-VDR-RXR
DPP4
Cyclin E
G-protein beta
KIR2DS2
Hsp90
Cyclin A
DNAJB7
AHR
Calpain
CCR3
ZAP70
Pka
Histone h3
Histone h4
TNFSF11
CCR2
G alphai
Hdac
Hsp70
cholecalciferol
BRCA1
C5AR1
RNA polymerase II
IL16
DUSP1
IFNG
G
GNAQ
Networks 1,2,3 Merged 13
 © 2000-2010 Ingenuity Systems, Inc. All rights reserved.
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    3-11 MOF hours 22-24 
  3-12 NMOF hours 22-24
 
Tlr
CXCL10
IL8
IL1
LDL
P38 MAPK
Jnk
IL12 (complex)
CCL2
Cyclooxygenase
IL1RN
MHC Class II
Ifn gamma
C1q
CCL11
MHC CLASS I (family)
CSF3
Fibrinogen
Nos
Mmp
STAT5a/b
HLA-DR
IL6
SAA@
Cpla2
Hat
NfkB-RelA
TNF
CSF2
IKK (complex)
Hsp27
Interferon alpha
IFN Beta
Hsp70
IgG
IG9
Vegf
MAP2K1/2
Cyclin E
NFkB (complex)
ERK
VitaminD3-VDR-RXR
Cyclin A
Hsp90
PI3K
DNAJB7
PDGF BB
Ap1
Calpain
IL-1R
Mek
AktERK1/2
Mapk
Histone h3
Histone h4
Il8r
Tgf beta
PLA2
STAT
Hdac
Rap1
Rac
KSR2
FAK
Ras
Nfat (family)
RNA polymerase II
IFNG
hCG
Networks 1,2 Merged 14
 © 2000-2010 Ingenuity Systems, Inc. All rights reserved.
 
Tlr
CXCL10
IL8
IL1
LDL
P38 MAPK
Jnk
IL12 (complex)
CCL2
Cyclooxygenase
IL1RN
MHC Class II
Ifn gamma
C1q
CCL11
MHC CLASS I (family)
CSF3
Fibrinogen
Nos
Mmp
STAT5a/b
HLA-DR
IL6
SAA@
Cpla2
Hat
NfkB-RelA
TNF
CSF2
IKK (complex)
Hsp27
Interferon alpha
IFN Beta
Hsp70
IgG
IG9
MAP2K1/2
Cyclin E
NFkB (complex)
ERK
VitaminD3-VDR-RXR
Cyclin A
Hsp90
PI3K
DNAJB7
PDGF BB
Ap1
TMEM158
Calpain
FAK
Mek
Akt
ERK1/2
Mapk
Histone h3
Histone h4
Il8r
Tgf beta
PLA2
STAT
Hdac
Rap1Rac
Vegf
Ras
AIM2
Nfat (family)
RNA polymerase II
IFNG
hCG
Networks 1,2 Merged 1
 © 2000-2010 Ingenuity Systems, Inc. All rights reserved.
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 Chapter 4 
 
Biological Networks generated from IPA in July 2007 (based on 11 cytokines) 
Graphic images were exported in January, 2011. Measured input molecules in pink 
to red; the darker the color, the higher the concentration. Solid lines are direct 
interactions; dotted lines, indirect interactions. Here, orange lines highlight the 
interactions involved in the functional relationship under examination, such as activation. 
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 4-1 MOF hours 6-10, Activation 
 
 4-2 NMOF hours 6-10, 
Activation 
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 4-3 MOF hours 6-10, Expression 
 
 4-4 NMOF hours 6-10, 
Expression 
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 4-5 MOF hours 6-10, Inhibition 
 
 4-6 NMOF hours 6-10, Inhibition 
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 4-7 MOF hours 6-10, 
Transcription 
 
 4-8 NMOF hours 6-10, 
Transcription 
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 4-9 MOF hours 10-14, Activation 
 
 
 4-10 NMOF hours 10-14, 
Activation
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 4-11 MOF hours 10-14, 
Expression 
 
 4-12 NMOF hours 10-14, 
Expression 
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 4-13 MOF hours 10-14, 
Inhibition 
 
 4-14 NMOF hours 10-14, 
Inhibition 
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 4-15 MOF hours 10-14, 
Transcription 
 
 4-16 NMOF hours 10-14, 
Transcription 
 
B/C)?
,1R
-)F
,10Q
,10
3B-
@3.3O)>!
<,A2
,22
V4=
B8A
@3.3
+F/?P
,10-0
<AH(:.<2
:)/=
<='WFX
K6E5
?????
<8NM(;;
B$'C77D$E64)F6
BB100
:+B(BC)FF(,,
345(%6'6/#7%
,1H
3E5(!6#)
:+B(BC)FF(,
B@M?
./0
:6=0>?
.=#
3IM
,=!
/PQ(@R=
,E6
J?M?
-I.(/7C$T6%)F6(,,
!"#$%&'()'&*
:B:A
:L8HH
JG+?
1G3@0
@30A
+,-.
J8IA
,1R-
J1<?
212A
B$'C&4(.
8,90
:;<
J1.K10
3<PA1
@B.-;0
B82U
+F/PQ
B$'C&4(J
B8HA
-.-;
8+M-
BBI.0
+&F#746(SA
+F/UQ
8HAQQOQV0Q-,2
:L;1?
<=)
3M8<0
,MIN
 
!+$0E
?5@
G0*
?56-
?56
8!G
7898O0IH
.?A;
?;;
\&/
!:A
7898
)*+E,
?56G6
.AM'F9.;
F0+/
./#S*X
L43B
?????
.:V='YY
!"#$112"34&0*4
!!566
F)!'!$0**'??8&B'C4#4+D1C
?5M
83B'H4D0
F)!'!$0**'?
!7=E
9+6
F4/6IE
9/D
8<=
?/H
+,-'7@/
?34
./0
G<9'+1$"R4C0*4'??
?G=E
FQ:MM
)7.965
.:(>:
)%*D1&4'PA
5[876
ZT%&1$%&%#'0#%U
786A
)?G9
:<9\9A
FQY5E
(5.E
;5;A
!"#$%&'9 :?N6
.N5GE=
(:<A
.:;6
8QG.6
9:!QO
)*+,-
!"#$%&'(
?=<96
!!<96
!G7.K'S%&#$TU4*'(VWK>>AX
)*+K-
=V=K
?=<V
:MA--O-\6-G?;
.!J9.
8=:.6 ???????????????????????????
9;9.6A
180 
 4-17 MOF hours 22-24, 
Activation 
 
 4-18 NMOF hours 22-24, 
Activation 
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 4-19 MOF hours 22-24, 
Expression 
 
 4-20 NMOF hours 22-24, 
Expression 
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 4-21 MOF hours 22-24, 
Inhibition  
 
 4-22 NMOF hours 22-24, 
Inhibition 
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 4-23 MOF hours 22-24, 
Transcription  
 
 4-24 NMOF hours 22-24, 
Transcription 
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